



6-19-06

IFW\$

Express Mail No. EQ 514894700 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Kunz *et al.*

Confirmation No.: 1690

Serial No.: 09/910,388

Art Unit: 1656

Filed: July 20, 2001

Examiner: Hope A. Robinson

For: THERAPEUTIC INHIBITOR OF
VASCULAR SMOOTH MUSCLE
CELLSAttorney Docket No.: 10177-211-999
CAM No.: 008563-999208

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure provisions of 37 C.F.R. §1.56, there is hereby provided certain information that the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the application.

The Examiner is advised that related European Patent No. 809515 was the subject of three Opposition proceedings before the Europe Patent Office and related European Patent No. 975340 was the subject of an Opposition Proceeding before the European Patent Office. Certain information relating to these proceedings and concerning coated medical devices, such as stents, was brought to Applicants' attention. The references designated by an asterisk (*) in the second column of the attached List of References include such information brought to Applicants' attention.

1. Enclosures accompanying this Information Disclosure Statement are:

1a. ☒ A list of all patents, publications, applications, or other information submitted for consideration by the office.

1b. A legible copy of:

☒ Each publication or that portion which caused it to be listed on the PTO-1449;☐ For each cited pending unpublished U.S. application, the application specification including the claims, and any drawing of the application, or portion of the application which caused it to be listed on the PTO-1449 including any claims directed to that portion that have been checked to be unavailable at the USPTO's private PAIR system;☐ An English language copy of search report(s) from a counterpart foreign application or PCT International Search Report;☒ Explanations of relevancy (ATTACHMENT 1(d), hereto) or English language abstracts of the non-English language publications;

- ☒ All other information or portion which caused it to be listed on the PTO-1449.
- 1c. ☒ Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and U.S. patent application publications are not submitted herewith unless required by the office.
- 1d. ☐ Pursuant to 1287 OG 163, copies of cited pending unpublished applications that are available at the USPTO's private PAIR system are not submitted herewith.
2. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b):
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under §1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in §1.491 in an international application;
 - ☐ Before the mailing of the first Office action on the merits;
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
3. ☒ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(c) after the period specified in 37 C.F.R. §1.97(b), but before the mailing date of any of a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311 or an action that otherwise closes prosecution in the application.

(Check either Item 3a or 3b)

- 3a. ☐ The Certification Statement in Item 5 below is applicable. Accordingly, no fee is required.
- 3b. ☒ The \$180.00 fee set forth in 37 C.F.R. §1.17(p) in accordance with 37 C.F.R. §1.97(c) is:
- ☐ enclosed.
 - ☒ to be charged to Jones Day Deposit Account No. 50-3013.

(Item 3b to be checked if any reference known for more than 3 months)

4. ☐ This Information Disclosure Statement is filed under 37 C.F.R. §1.97(d) after the period specified in 37 C.F.R. §1.97(c), but on or before the date of payment of the issue fee.

The Certification Statement in Item 5 below is applicable.

The \$180.00 fee set forth in 37 C.F.R. §1.17(p) is:

- ☐ enclosed.
- ☐ to be charged to Jones Day Deposit Account No. 50-3013.

5. ☐ Certification Statement (applicable if Item 3a or Item 4 is checked):

(Check either Item 5a or 5b)

- 5a. ☐ In accordance with 37 C.F.R. §1.97(e)(1), it is certified that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

- 5b. ☐ Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 5c. ☐ Pursuant to 37 C.F.R. §1.704(d), each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and the communication was not **received** by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this information disclosure statement.
6. ☒ This application is a continuation application under 37 C.F.R. §1.53(b) or (d).
(Check appropriate Items 6a, 6b and/or 6c)
- 6a. ☐ A Petition to Withdraw from issue under 37 C.F.R. §1.313(b)(5) is concurrently filed herewith.
- 6b. ☒ Copies of publications listed on Form PTO-1449 from prior application Serial No. 09/470,662, filed on December 22, 1999, of which this application claims priority under 35 U.S.C. §120, are not being submitted pursuant to 37 C.F.R. §1.98(d).
- 6c. ☒ Copies of the publications listed on Form PTO-1449 that were not previously cited in prior application Serial No. 09/470,662, filed on December 22, 1999, and are provided herewith.
7. ☐ This is a Supplemental Information Disclosure Statement. (Check Item 7a)
- 7a. ☐ This Supplemental Information Disclosure Statement under 37 C.F.R. §1.97(f) supplements the Information Disclosure Statement filed on . A bona fide attempt was made to comply with 37 C.F.R. §1.98, but inadvertent omissions were made. These omissions have been corrected herein. Accordingly, additional time is requested so that this Supplemental Information Disclosure Statement can be considered as if properly filed on .
8. ☒ In accordance with 37 C.F.R. §1.98, a concise explanation of what is presently understood to be the relevance of each non-English language publication is:
(Check Item 8a, 8b, or 8c)
- 8a. ☐ Satisfied because all non-English language publications were cited on the enclosed English language copy of the PCT International Search Report or the search report from a counterpart foreign application indicating the degree of relevance found by the foreign office.
- 8b. ☐ Set forth in the application.
- 8c. ☒ Enclosed as an attachment hereto.
9. ☒ The Commissioner is authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement and/or Petition to Jones Day Deposit Account No. 50-3013.
10. ☒ No admission is made that the information cited in this Statement is, or is considered to be, material to patentability and no representation is made that a search has been made

(other than a search report of a foreign counterpart application or PCT International Search Report if submitted herewith). 37 C.F.R. §§1.97(g) and (h).


Respectfully submitted,

Date: June 16, 2006



Gidon D. Stern (Reg. No. 27,469)

By:



Linda B. Azria (Reg. No. 44,516)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

10177-211-999

APPLICATION NO.

09/910,388

APPLICANT

Kunz *et al.*

FILING DATE

July 20, 2001

GROUP

1656

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,783,543	08/31/04	Jang			
	A02	6,764,507	07/20/04	Shanley, et al.			
	A03	6,689,159	02/10/04	Lau, et al.			
	A04	6,663,881	12/16/03	Kunz, et al.			
	A05	6,656,216	12/02/03	Nossainy, et al.			
	A06	6,656,162	12/02/03	Santini Jr., et al.			
	A07	6,616,765	09/09/03	Castro, et al.			
	A08	6,616,690	09/09/03	Rolando, et al.			
	A09	6,599,928	07/29/03	Kunz, et al.			
	A10	6,596,022	07/22/03	Lau, et al.			
	A11	6,575,993	07/10/03	Yock			
	A12	6,562,065	05/13/03	Shanley			
	A13	6,555,138	04/29/03	Karlsson			
	A14	6,544,790	04/08/03	Sabatini			
	A15	6,544,544	04/08/03	Hunter, et al.			
	A16	6,527,789	03/04/03	Lau, et al.			
	A17	6,515,009	02/04/03	Kunz, et al.			
	A18	6,497,647	12/24/02	Tucker			
	A19	6,492,106	12/10/02	Sabatini et al.			
	A20	6,491,617	12/10/02	Ogle, et al.			
	A21	6,488,694	12/03/02	Lau, et al.			
	A22	6,485,511	11/26/02	Lau, et al.			
	A23	6,476,200	11/05/02	Sabatini, et al.			
	A24	6,461,381	10/08/02	Israel, et al.			
	A25	6,443,982	09/03/02	Israel, et al.			
	A26	6,432,133	08/13/02	Lau, et al.			
	A27	6,429,232	08/06/02	Kinsella, et al.			
	A28	6,395,326	05/28/02	Castro, et al.			
	A29	6,309,414	10/30/01	Rolando, et al.			
	A30	6,309,412	10/30/01	Lau, et al.			
	A31	6,306,421	10/23/01	Kunz, et al.			
	A32	6,251,920	06/26/01	Grainger, et al.			
	A33	6,241,762	06/05/01	Shanley			
	A34	6,210,393	04/03/01	Brisken, et al.			
	A35	6,203,536	03/20/01	Berg, et al.			

	A36	6,198,016	03/06/01	Lucast, et al.			
	A37	6,187,370	02/13/01	Dinh, et al.			
	A38	6,168,619	01/02/01	Dinh, et al.			
	A39	6,152,869	11/28/00	Park, et al.			
	A40	6,146,358	11/14/00	Rowe			
	A41	6,133,242	10/17/00	Zalewski, et al.			
	A42	6,129,757	10/10/00	Weadock			
	A43	6,120,536	09/19/00	Ding, et al.			
	A44	6,110,483	08/29/00	Whitbourne, et al.			
	A45	6,106,454	08/22/00	Berg, et al.			
	A46	6,099,562	08/08/00	Ding, et al.			
	A47	6,099,499	08/08/00	Ciamacco, et al.			
	A48	6,096,070	08/01/00	Ragheb, et al.			
	A49	6,093,142	07/25/00	Kunz, et al.			
	A50	6,086,910	07/11/00	Howard, et al.			
	A51	6,074,659	06/13/00	Kunz, et al.			
	A52	6,074,337	06/13/00	Tucker et al.			
	A53	6,066,167	05/23/00	Lau, et al.			
	A54	6,042,875	03/28/00	Ding, et al.			
	A55	6,036,715	03/14/00	Yock			
	A56	6,033,866	02/08/00	Falk, et al.			
	A57	6,013,099	01/11/00	Dinh, et al.			
	A58	6,001,622	12/14/99	Dedhar, et al.			
	A59	5,990,095	11/23/99	Falk, et al.			
	A60	5,981,568	11/09/99	Kunz, et al.			
	A61	5,980,972	11/09/99	Ding			
	A62	5,972,018	10/26/99	Israel, et al.			
	A63	5,948,639	09/07/99	Ginemo, et al.			
	A64	5,902,332	05/11/99	Schatz			
	A65	5,900,246	05/04/99	Lambert			
	A66	5,877,224	03/02/99	Brocchini, et al.			
	A67	5,873,904	02/23/99	Ragheb, et al.			
	A68	5,863,285	01/26/99	Coletti			
	A69	5,849,034	12/15/98	Schwartz			
	A70	5,847,007	12/08/98	Grainger, et al.			
	A71	5,843,120	12/01/98	Israel, et al.			
	A72	5,837,313	11/17/98	Ding, et al.			
	A73	5,837,008	11/17/98	Berg, et al.			
	A74	5,824,647	10/20/98	Postlethwaite, et al.			
	A75	5,824,054	10/20/98	Khosravi, et al.			
	A76	5,824,049	10/20/98	Ragheb, et al.			
	A77	5,821,234	10/13/98	Dzau.			
	A78	5,811,447	09/22/98	Kunz, et al.			
	A79	5,800,507	09/01/98	Schwartz			

	A80	5,797,898	08/25/98	Santini Jr., et al.			
	A81	5,779,732	07/14/98	Amundson			
	A82	5,773,479	06/30/98	Grainger, et al.			
	A83	5,770,609	06/23/98	Grainger, et al.			
	A84	5,767,079	06/16/98	Glaser, et al.			
	A85	5,749,915	05/12/98	Slepian			
	A86	5,749,888	05/12/98	Yock			
	A87	5,747,510	05/05/98	Draper			
	A88	5,735,897	04/07/98	Buirge			
	A89	5,733,303	03/31/98	Israel, et al.			
	A90	5,731,424	03/24/98	Toothman, et al.			
	A91	5,731,200	03/24/98	Ichijo, et al.			
	A92	5,731,144	03/24/98	Toothman, et al.			
	A93	5,726,186	03/10/98	Grese			
	A94	5,722,984	03/03/98	Fischell, et al.			
	A95	5,705,609	01/06/98	Ruoslahti, et al.			
	A96	5,705,477	01/06/98	Sporn, et al.			
	A97	5,700,559	12/23/97	Sheu, et al.			
	A98	5,697,967	12/16/97	Dinh, et al.			
	A99	5,693,607	12/02/97	Segrini, et al.			
	A100	5,688,855	11/18/97	Stoy, et al.			
	A101	5,688,813	11/18/97	Sall, et al.			
	A102	5,686,476	11/11/97	May			
	A103	5,686,467	11/11/97	Bumol, et al.			
	A104	5,681,835	10/28/97	Willson			
	A105	5,679,400	10/21/97	Tuch			
	A106	5,667,764	09/16/97	Kopia, et al.			
	A107	5,662,712	09/02/97	Pathak, et al.			
	A108	5,660,873	08/26/97	Nikolaychik, et al.			
	A109	5,658,951	08/19/97	Magarian, et al.			
	A110	5,658,927	08/19/97	Magarian, et al.			
	A111	5,658,883	08/19/97	Ogawa, et al.			
	A112	5,656,587	08/12/97	Sporn, et al.			
	A113	5,656,450	08/12/97	Boyan, et al.			
	A114	5,652,259	07/29/97	May			
	A115	5,651,627	07/29/97	Dowzall, et al.			
	A116	5,643,580	07/01/97	Subramanian			
	A117	5,641,790	06/24/97	Draper			
	A118	5,639,738	06/17/97	Falk, et al.			
	A119	5,639,274	06/17/97	Fischell, et al.			
	A120	5,637,113	06/10/97	Tartaglia, et al.			
	A121	5,635,489	06/03/97	Haley			
	A122	5,632,840	05/27/97	Campbell			
	A123	5,629,077	05/13/97	Turnlund, et al.			

	A124	5,626,600	05/06/97	Horzewski, et al.			
	A125	5,622,975	04/22/97	Singh, et al.			
	A126	5,610,168	03/11/97	Draper			
	A127	5,610,166	03/11/97	Singh			
	A128	5,609,629	03/11/97	Fearnott, et al.			
	A129	5,607,463	03/04/97	Schwartz, et al.			
	A130	5,605,700	02/25/97	DeGregorio, et al.			
	A131	5,605,696	02/25/97	Eury, et al.			
	A132	5,599,844	02/04/97	Grainger, et al.			
	A133	5,597,578	01/28/97	Brown, et al.			
	A134	5,595,722	11/21/97	Grainger, et al.			
	A135	5,591,224	01/07/97	Schwartz, et al.			
	A136	5,583,153	12/10/96	Brahn			
	A137	5,580,898	12/03/96	Trojanowski, et al.			
	A138	5,578,703	11/16/96	Ichijo, et al.			
	A139	5,578,075	11/26/96	Dayton			
	A140	5,576,345	11/19/96	Mansson, et al.			
	A141	5,574,047	11/12/96	Bumol, et al.			
	A142	5,571,808	11/05/96	Leeds			
	A143	5,571,714	11/05/96	Dasch, et al.			
	A144	5,571,166	11/05/96	Dinh, et al.			
	A145	5,569,463	10/29/96	Helmus, et al.			
	A146	5,567,713	10/22/96	Cullinan, et al.			
	A147	5,563,054	10/08/96	Briggs, et al.			
	A148	5,562,922	10/08/96	Lambert			
	A149	5,556,876	09/17/96	Bryant, et al.			
	A150	5,554,182	09/10/96	Dinh, et al.			
	A151	5,552,433	09/03/96	Bryant, et al.			
	A152	5,552,415	09/03/96	May			
	A153	5,551,954	09/03/96	Buscemi, et al.			
	A154	5,545,569	08/13/96	Grainger, et al.			
	A155	5,545,409	08/13/96	Laurencin, et al.			
	A156	5,545,208	08/13/96	Wolff, et al.			
	A157	5,543,155	08/06/96	Fekete, et al.			
	A158	5,541,174	07/30/96	Sorenson			
	A159	5,538,892	06/23/96	Donahoe, et al.			
	A160	5,534,527	07/09/96	Black, et al.			
	A161	5,525,624	06/11/96	Gitter, et al.			
	A162	5,523,092	06/04/96	Hanson, et al.			
	A163	5,521,198	05/28/96	Zuckerman			
	A164	5,521,191	05/28/96	Greenwald			
	A165	5,521,172	05/28/96	Bryant, et al.			
	A166	5,521,171	05/28/96	Sorenson			
	A167	5,516,807	05/14/96	Hupe, et al.			

	A168	5,514,154	05/07/96	Lau, et al.			
	A169	5,510,370	04/23/96	Hock, et al.			
	A170	5,510,077	04/23/96	Dinh, et al.			
	A171	5,508,292	04/16/96	Sall, et al.			
	A172	5,500,013	03/19/96	Buschemi, et al.			
	A173	5,498,775	03/12/96	Novak, et al.			
	A174	5,496,851	03/05/96	Grinnell			
	A175	5,496,828	03/05/96	Cullinan			
	A176	5,496,557	03/05/96	Feijen, et al.			
	A177	5,496,346	03/05/96	Horzewski, et al.			
	A178	5,492,927	02/20/96	Gitter, et al.			
	A179	5,492,926	02/20/96	Cullinan, et al.			
	A180	5,492,922	02/20/96	Palkowitz			
	A181	5,492,921	02/20/96	Bryant, et al.			
	A182	5,492,895	02/20/96	Vlasuk, et al.			
	A183	5,491,173	02/13/96	Toivola, et al.			
	A184	5,491,159	02/13/96	Malamas			
	A185	5,489,587	02/06/96	Fontana			
	A186	5,486,357	01/23/96	Narayanan			
	A187	5,484,808	01/16/96	Grinnell			
	A188	5,484,798	01/16/96	Bryant, et al.			
	A189	5,484,797	01/16/96	Bryant, et al.			
	A190	5,484,796	01/16/96	Bryant, et al.			
	A191	5,484,795	01/16/96	Bryant, et al.			
	A192	5,482,950	01/09/96	Bryant, et al.			
	A193	5,482,949	01/09/96	Black, et al.			
	A194	5,482,851	01/09/96	Derynck, et al.			
	A195	5,480,904	01/02/96	Bryant, et al.			
	A196	5,480,903	01/02/96	Piggott, et al.			
	A197	5,480,888	01/02/96	Kodama, et al.			
	A198	5,478,847	12/26/95	Draper			
	A199	5,472,985	12/05/95	Grainger, et al.			
	A200	5,470,883	11/28/95	Stromberg			
	A201	5,470,876	11/28/95	Proctor			
	A202	5,466,810	11/14/95	Godfrey			
	A203	5,464,450	11/07/95	Buscemi, et al.			
	A204	5,462,950	10/31/95	Fontana			
	A205	5,462,949	10/31/95	Jones, et al.			
	A206	5,462,937	10/31/95	Cullinan, et al.			
	A207	5,461,065	10/24/95	Black, et al.			
	A208	5,461,064	10/24/95	Cullinan, G.J.			
	A209	5,457,117	10/10/95	Black, et al.			
	A210	5,457,116	10/10/95	Black, et al.			
	A211	5,457,113	10/10/95	Cullinan, et al.			

	A212	5,455,275	10/03/95	Fontana			
	A213	5,453,492	09/26/95	Butzow, et al.			
	A214	5,453,442	09/26/95	Bryant, et al.			
	A215	5,451,603	09/19/95	Piggott			
	A216	5,451,590	09/19/95	Dodge			
	A217	5,451,589	09/19/95	Dodge			
	A218	5,451,414	09/19/95	Steward			
	A219	5,451,233	09/19/95	Yock			
	A220	5,449,382	09/12/95	Dayton			
	A221	5,447,941	09/05/95	Zuckerman			
	A222	5,447,724	09/05/95	Helmus, et al.			
	A223	5,446,070	08/29/95	Mantelle			
	A224	5,446,053	08/29/95	Keohane			
	A225	5,445,941	08/29/95	Yang			
	A226	5,443,458	08/22/95	Eury			
	A227	5,441,986	08/15/95	Thompson			
	A228	5,441,966	08/15/95	Dodge			
	A229	5,441,965	08/15/95	Sall, et al.			
	A230	5,441,964	08/15/95	Bryant, et al.			
	A231	5,441,734	08/15/95	Reichert, et al.			
	A232	5,439,931	08/08/95	Sales			
	A233	5,439,923	08/08/95	Cullinan			
	A234	5,439,689	08/08/95	Hendrickson, et al.			
	A235	5,436,243	07/25/95	Sachs, et al.			
	A236	5,434,166	07/18/95	Glasebrook			
	* A237	5,429,634	07/04/95	Narcisco, et al.			
	A238	5,429,618	07/04/95	Keogh			
	A239	5,426,123	06/20/95	Fontana			
	A240	5,424,331	06/13/95	Shlyankevich			
	A241	5,421,955	06/06/95	Lau, et al.			
	A242	5,420,243	05/30/95	Ogawa, et al.			
	A243	5,419,760	05/30/95	Narciso, Jr.			
	A244	5,418,252	05/23/95	Williams			
	A245	5,415,619	05/16/95	Lee, et al.			
	A246	5,411,988	05/02/95	Bockow, et al.			
	A247	5,407,658	04/18/95	Hattner			
	A248	5,407,609	04/18/95	Tice, et al.			
	A249	5,401,730	03/28/95	Sauvage, et al.			
	A250	5,399,352	03/21/95	Hanson			
	A251	5,395,842	03/07/95	Labrie, et al.			
	A252	5,393,785	02/28/95	Labrie, et al.			
	A253	5,391,557	02/21/95	Cullinan, et al.			
	A254	5,391,378	02/21/95	Sanderson			
	A255	5,389,670	02/14/95	Fontana			

		A256	5,384,332	01/24/95	Fontana			
		A257	5,383,928	01/24/95	Scott, et al.			
		A258	5,380,299	01/10/95	Fearnot, et al.			
		A259	5,378,475	01/03/95	Smith, et al.			
		A260	5,356,433	10/18/94	Rowland, et al.			
		A261	5,354,801	10/11/94	O'toole, et al.			
		A262	5,344,926	09/13/94	Murakata, et al.			
		A263	5,342,926	08/30/94	Hattner			
	*	A264	5,342,348	08/30/94	Kaplan			
		A265	5,338,770	08/16/94	Winters, et al.			
		A266	5,332,576	07/26/94	Mantelle			
		A267	5,324,739	06/28/94	Germick, et al.			
		A268	5,318,779	06/07/94	Hakamatsuka, et al.			
		A269	5,308,889	05/03/94	Rhee, et al.			
		A270	5,304,121	04/19/94	Sahatjian			
		A271	5,302,584	04/12/94	Kao, et al.			
		A272	5,292,802	03/08/94	Rhee, et al.			
		A273	5,290,271	03/01/94	Jernberg			
		A274	5,282,823	02/01/94	Schwartz, et al.			
		A275	5,280,040	01/18/94	Labroo, et al.			
		A276	5,262,451	11/16/93	Winters, et al.			
		A277	5,262,319	11/16/93	Iwata, et al.			
		A278	5,258,020	11/02/93	Froix			
		A279	5,234,957	08/10/93	Mantelle			
	*	A280	5,234,456	08/10/93	Silverstrini			
		A281	5,226,913	07/13/93	Pinchuk			
		A282	5,222,971	06/29/93	Willard, et al.			
		A283	5,216,021	06/01/93	Sorenson			
		A284	5,211,940	05/18/93	Ishiguro, et al.			
		A285	5,199,951	04/06/93	Spears			
		A286	5,195,984	03/23/93	Schatz			
		A287	5,185,408	02/09/93	Tang, et al.			
		A288	5,182,317	01/26/93	Winters, et al.			
		A289	5,180,376	01/19/93	Fischell			
		A290	5,167,960	12/01/92	Ito, et al.			
		A291	5,166,191	11/24/92	Cronin, et al.			
		A292	5,163,952	11/17/92	Froix			
		A293	5,145,838	09/08/92	Pickart			
		A294	5,145,684	09/08/92	Liversidge, et al.			
		A295	5,126,348	06/30/92	McMurray.			
		A296	5,118,791	06/02/92	Burnier, et al.			
		A297	5,114,847	05/19/92	Jungfer, et al.			
		A298	5,108,989	05/28/92	Amento, et al.			
		A299	5,102,417	04/07/92	Palmaz			

	A300	5,100,885	03/31/92	Abrams, et al.			
	A301	5,099,504	03/24/92	Pettit			
	A302	5,092,877	03/03/92	Pinchuk			
	A303	5,082,834	01/21/92	Sorenson			
	A304	5,075,321	12/24/91	Schreiber			
	A305	5,064,435	11/12/91	Porter			
	A306	5,061,275	10/29/91	Wallsten, et al.			
	A307	5,061,273	10/29/91	Yock			
	A308	5,053,048	10/01/91	Pinchuk, et al.			
	A309	5,040,548	08/20/91	Yock			
	A310	5,037,641	08/06/91	Juhos, et al.			
	A311	5,034,265	07/23/91	Hoffman, et al.			
	A312	5,030,637	07/09/91	Einzig, et al.			
	A313	5,023,237	06/11/91	Pickart, et al.			
	A314	5,019,504	05/28/91	Christen, et al.			
	A315	5,008,279	04/16/91	Franckowiak, et al.			
	A316	5,002,531	03/26/91	Bonzel			
	A317	4,999,347	03/12/91	Sorenson			
	A318	4,996,225	02/26/91	Toivola, et al.			
	A319	4,994,384	02/19/91	Prather, et al.			
	A320	4,994,071	02/19/91	McGregor			
	A321	4,990,158	02/05/91	Kaplan, et al.			
	A322	4,984,594	01/15/91	Vinegar, et al.			
	A323	4,973,755	11/27/90	Gafe, et al.			
	A324	4,973,601	11/27/90	Dowd, et al.			
	A325	4,959,355	09/25/90	Fischbarg, et al.			
	A326	4,956,188	09/11/90	Anderson			
	A327	4,954,126	09/04/90	Wallsten			
	A328	4,952,607	08/28/90	Sorenson			
	A329	4,922,905	05/08/90	Strecker			
	A330	4,916,193	04/10/90	Tang, et al.			
	A331	4,900,561	02/13/90	Abdel-Monem, et al.			
	A332	4,886,062	12/12/89	Wiktor			
	A333	4,872,867	10/10/89	Joh, et al.			
	A334	4,853,377	08/01/89	Pollack,			
	A335	4,840,939	06/20/89	Leveen, et al.			
	A336	4,824,661	04/25/89	Wagner			
	A337	4,793,348	12/27/88	Palmaz			
	A338	4,786,500	11/22/88	Wong			
	A339	4,776,337	10/11/88	Palmaz			
	A340	4,767,758	08/30/88	Breccia, et al.			
	A341	4,762,129	08/09/88	Bonzel			
	A342	4,760,051	07/26/88	Pickart			
	A343	4,758,555	07/19/88	Sorenson			

	A344	4,758,554	07/19/88	Sorenson, et al.			
	A345	4,757,059	07/12/88	Sorenson			
	A346	4,753,652	06/28/88	Langer, et al.			
	A347	4,748,982	06/07/88	Horzewski, et al.			
	A348	4,739,762	04/26/88	Palmaz			
	A349	4,733,665	03/29/88	Palmaz			
	A350	4,705,647	11/10/87	Yamaguchi, et al.			
	A351	4,696,949	08/29/87	Toivola, et al.			
	A352	4,689,046	08/25/87	Bokros			
	A353	4,687,482	08/18/87	Hanson			
	A354	4,678,466	07/07/87	Rosenwald			
	A355	4,670,428	06/02/87	Sorenson			
	A356	4,664,097	05/12/87	McGrath, et al.			
	A357	4,657,928	04/14/87	Sorenson			
	A358	4,656,083	04/07/87	Hoffman, et al.			
	A359	4,655,771	04/07/87	Wallsten			
	A360	4,629,694	12/16/86	Harpel			
	A361	4,613,665	09/23/86	Larm			
	A362	4,605,644	08/12/86	Foker			
	A363	4,536,516	08/20/85	Harper, et al.			
	A364	4,491,574	01/01/85	Seifter, et al.			
	A365	4,487,780	12/11/84	Scheinberg			
	A366	4,440,754	04/03/84	Sorenson			
	A367	4,428,963	01/31/84	Confalone, et al.			
	A368	4,418,068	11/29/83	Jones			
	A369	4,382,143	05/03/83	Shepherd			
	A370	4,380,635	04/19/83	Peters			
	A371	4,339,429	07/13/82	Raaf, et al.			
	A372	4,332,791	06/01/82	Raaf, et al.			
	A373	4,323,707	04/06/82	Suarez, et al.			
	A374	4,317,915	03/02/82	Confalone, et al.			
	A375	4,315,028	02/09/82	Scheinberg			
	A376	4,310,523	01/12/82	Neumann			
	A377	4,307,111	12/22/81	Crawley			
	A378	4,300,244	11/17/81	Bokros			
	A379	4,292,965	10/06/81	Nash, et al.			
	A380	4,287,190	09/01/81	Boettcher, et al.			
	A381	4,282,246	08/04/81	Holland			
	A382	4,239,778	12/16/80	Venton, et al.			
	A383	4,230,862	10/28/80	Suarez, et al.			
	A384	4,221,785	09/09/80	Sorenson			
	A385	4,219,656	08/26/80	Press, et al.			
	A386	4,219,520	08/26/80	Kline			
	A387	4,205,685	06/03/80	Yoshida, et al.			

	A388	4,133,814	01/09/79	Jones, et al.			
	A389	3,952,334	04/27/76	Bokros, et al.			
	A390	3,932,627	01/13/76	Margaf			
	A391	3,879,516	04/22/75	Wolvek			
	A392	3,738,365	06/12/73	Schulte			
	A393	3,634,517	01/11/72	Palopoli, et al.			
	A394	3,526,005	09/01/70	Bokros, et al.			
	A395	3,445,473	05/20/69	Ruschig, et al.			
	A396	3,288,806	11/29/66	Dewald, et al.			
	A397	3,279,996	10/18/66	Long, et al.			
	A398	3,168,565	02/02/65	Palopoli, et al.			
	A399	3,010,965	11/28/61	Elpern			
	A400	2,914,563	11/24/59	Allen, et al.			
	A401	2004/0236416	11/25/04	Falotico			
	A402	2002/0091433	07/11/02	Ding, et al.			
	A403	2002/0032477	03/14/02	Helmus, et al.			
	A404	2002/0013275	01/31/02	Kunz, et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	31079/93	07/15/93	Australian Patent Application				
	B02	03-297469	12/27/91	Japan (with English abstract)				
	B03	06-121828	06/05/94	Japan (with English abstract)				
	B04	06-205838	07/26/94	Japan (with English abstract)				
	B05	08-33718	02/06/96	Japan (with English abstract)				
	B06	09-255570	03/21/96	Japan				
	B07	59-042375	03/08/84	Japan				
	B08	60-25288	02/01/94	Japan				
	B09	1 015 787	01/05/96	United Kingdom				
	B10	1 587 084	05/25/81	United Kingdom				
	B11	2 273 873	06/07/94	United Kingdom				
	B12	1 205 743	07/15/96	United Kingdom				
	B13	2 153 253	01/25/85	United Kingdom				
	B14	2,231,727	09/14/04	Canada				
	B15	2,079,205	03/26/94	Canada				
	B16	2,086,642	07/10/93	Canada				
	B17	2,207,659	06/13/96	Canada				
	B18	2255063	07/18/75	France				
	B19	4320896	01/05/95	Germany				
	B20	4320898	01/05/95	Germany				
	B21	4401554	08/18/94	Germany				
	B22	DE A 3 918 736	12/13/90	Germany (with English abstract)				
	B23	DE A 40 22 956	02/06/92	Germany (with English abstract)				
	B24	1247527	04/24/91	Italy				

		B25	EP 0 095 875 A2	12/07/83	Europe				
		B26	EP 0 002 341	06/13/79	Europe				
		B27	EP 0 024 096	02/25/81	Europe				
		B28	EP 0 054 168 A1	06/23/82	Europe				
		B29	EP 0 524 093	01/20/93	Europe				
		B30	EP 0 566 245 A1	10/20/93	Europe				
	*	B31	EP 0 578 998	01/1994	Europe				
		B32	EP 0 604 022 A1	06/29/94	Europe				
	*	B33	EP 0 619 314	10/12/94	Europe				
		B34	EP 0 621 015 A1	04/23/04	Europe				
		B35	EP 0 623 345 A1	05/03/94	Europe				
		B36	EP 0 639 577	02/22/95	Europe				
		B37	EP 0 673 936	09/27/95	Europe				
		B38	EP 0 701 802 A1	03/20/93	Europe				
		B39	EP 0 706 376 B1	06/25/97	Europe				
		B40	EP 0 716 836 A1	12/11/95	Europe				
	*	B41	EP 0 717 041 B1	06/19/96	Europe				
		B42	EP 0 734 721 A2	10/02/96	Europe				
	*	B43	EP 0 747 069	12/11/96	Europe				
		B44	EP 0 975 340	10/08/98	Europe				
		B45	EP 1 360 967 A1	11/12/03	Europe				
		B46	EP A 0 430 542	11/20/90	Europe				
		B47	EP A 0 435 518	12/13/90	Europe				
		B48	EP 0 290 012	11/09/88	Europe				
		B49	EP 0 302 034	02/01/89	Europe				
		B50	EP 0 635 270	01/25/95	Europe				
		B51	EP 0 377 526B1	07/11/90	Europe				
		B52	EP 0 524 093	01/20/93	Europe				
		B53	EP 0 542 679	05/19/93	Europe				
		B54	EP 0 551 182	07/14/93	Europe				
	*	B55	EP 0 623 354	11/09/94	Europe				
		B56	EP 0 629 697	12/21/94	Europe				
		B57	EP 0 639 577	02/22/95	Europe				
		B58	EP 0 659 413 A2	06/28/95	Europe				
		B59	EP 0 659 415 A2	06/28/95	Europe				
		B60	EP 0 659 418	06/28/95	Europe				
		B61	EP 0 659 419 A1	06/28/95	Europe				
		B62	EP 0 659 429 A1	06/28/95	Europe				
		B63	EP 0 664 121	07/26/95	Europe				
		B64	EP 0 664 122	07/26/95	Europe				
		B65	EP 0 664 123	07/26/95	Europe				
		B66	EP 0 664 124 A1	07/26/95	Europe				
		B67	EP 0 664 125	07/26/95	Europe				
		B68	EP 0 664 198	07/26/95	Europe				
		B69	EP 0 665 015 A2	08/02/95	Europe				

	B70	EP 0 668 075 A2	08/23/95	Europe				
	B71	EP 0 670 162	09/06/95	Europe				
	B72	EP 0 673 936	09/27/95	Europe				
	B73	EP 0 674 903	10/04/95	Europe				
	B74	EP 0 675 121	10/04/95	Europe				
	B75	EP 0 684 259 A1	11/29/95	Europe				
	B76	EP 0 699 673	03/06/96	Europe				
	B77	EP 0 734 721 A2	02/10/96	Europe				
	B78	WO 00/00238	01/06/00	PCT				
	B79	WO 0047197	08/17/00	PCT				
	B80	WO 89/03232	04/20/89	PCT				
	B81	WO 90/07328	07/12/90	PCT				
	B82	WO 91/08291	06/13/91	PCT				
	B83	WO 91/17789 A1	11/28/91	PCT				
	B84	WO 91/18940 A1	12/12/91	PCT				
	B85	WO 92/00330	01/09/92	PCT				
	B86	WO 92/06068	04/16/92	PCT				
	B87	WO 92/13867	08/20/92	PCT				
	B88	WO 92/19612	11/12/92	PCT				
	B89	WO 93/02065	02/04/93	PCT				
	B90	WO 93/04191	03/04/93	PCT				
	B91	WO 93/09228	05/13/93	PCT				
	B92	WO 93/09790	05/27/93	PCT				
	B93	WO 93/09800	05/27/93	PCT				
	B94	WO 93/09802	05/27/93	PCT				
	B95	WO 93/10808	06/10/93	PCT				
	B96	WO 93/11757	06/24/93	PCT				
	B97	WO 93/16724	09/02/93	PCT				
	B98	WO 93/19746	10/14/93	PCT				
	B99	WO 93/19769	10/14/93	PCT				
	B100	WO 94/01056	01/20/94	PCT				
	B101	WO 94/02595	02/03/94	PCT				
	B102	WO 94/07529	04/14/94	PCT				
	B103	WO 94/09010	04/28/94	PCT				
	B104	WO 94/09764	05/11/94	PCT				
	B105	WO 94/09812	05/11/94	PCT				
	B106	WO 94/10187	05/11/94	PCT				
*	B107	WO 94/13706	06/23/94	PCT				
	B108	WO 94/15589	07/21/94	PCT				
	B109	WO 94/16706	08/04/94	PCT				
	B110	WO 94/20098	09/15/94	PCT				
	B111	WO 94/20099	09/15/94	PCT				
	B112	WO 94/20116	09/15/94	PCT				
	B113	WO 94/20117	09/15/94	PCT				
	B114	WO 94/20126	09/15/94	PCT				

		B115	WO 94/20127	09/15/94	PCT				
		B116	WO 94/21309	09/29/94	PCT				
		B117	WO 94/23068	10/13/94	PCT				
		B118	WO 94/23699	10/27/94	PCT				
		B119	WO 94/24961	11/10/94	PCT				
		B120	WO 94/25053	11/10/94	PCT				
		B121	WO 94/25588	11/10/94	PCT				
	*	B122	WO 94/26291	11/24/94	PCT				
		B123	WO 94/26303	11/24/94	PCT				
		B124	WO 94/26888	10/06/95	PCT				
		B125	WO 94/27612	12/08/94	PCT				
		B126	WO 95/04544	02/16/95	PCT				
		B127	WO 95/05191	02/23/95	PCT				
		B128	WO 95/10611	04/20/95	PCT				
		B129	WO 95/17095	06/29/95	PCT				
		B130	WO 95/19987	07/27/95	PCT				
		B131	WO 95/20582	08/03/95	PCT				
		B132	WO 95/30900	11/16/95	PCT				
		B133	WO 95/33736	12/14/95	PCT				
		B134	WO 96/01102	01/18/96	PCT				
	*	B135	WO 96/03092	02/08/96	PCT				
		B136	WO 96/07402	03/14/96	PCT				
		B137	WO 96/15224	05/23/96	PCT				
		B138	WO 96/20698	07/11/96	PCT				
		B139	WO 96/21442	07/18/96	PCT				
		B140	WO 96/21443	07/18/96	PCT				
		B141	WO 96/24356	08/15/96	PCT				
	*	B142	WO 96/25176	08/22/96	PCT				
		B143	WO 96/32907	10/24/96	PCT				
		B144	WO 96/36349	11/21/96	PCT				
		B145	WO 96/40098	12/19/96	PCT				
		B146	WO 97/10011	03/20/97	PCT				
		B147	WO 97/10334	03/20/97	PCT				
		B148	WO 97/15319	05/01/97	PCT				
		B149	WO 97/21455	06/19/97	PCT				
		B150	WO 97/22697	06/26/97	PCT				
		B151	WO 97/33552	09/18/97	PCT				
		B152	WO 97/45105	12/04/97	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

		C01	"Breast Cancer Prevention Trial Should Resume, ODAC Says", <i>The Breast Cancer Letter</i> , 20, 4-5, (June 17, 1994)
		C02	"Churchill's Medical Dictionary", <i>definition of "cytostatic"</i> , 473, (1989)
		C03	"Coronary Artery Disease: Restenosis and Reocclusion After Surgical and Nonsurgical Interventions, Part 1", <i>Durg and Market Development</i> , 5, 121-129 (Sept. 26, 1994)
		C04	"Glaxo Wellcome Preclinical Data: Preclinical studies conducted with GW 5638, a selective estrogen receptor modulator developed by Glaxo Wellcome, indicate that the compound acts both as an agonist and antagonist at estrogen receptor within specific ...", <i>R & D Focus Drug News</i> , (September 8, 1997)

	C05	"Growth Factor Via Gene Therapy Abates Sore Rheumatoid Joints", BioWorld Today: The Daily Biotechnology Newspaper, 9(115), Leff, David N., Editor, 1, (June 17, 1998)
	C06	"Health Report -- The Good News", Time, 23, (Apr. 1, 1996)
	C07	"Heparin", In: Modern Pharmacology, Craig, C.R., et al., (eds.), Little, Brown and Company, Boston, MA, p. 399, (1982)
	C08	"ICI United States, Inc., Tamoxifen citrate, Summary For Basis of Approval", (December 30, 1977)
	C09	"Johnson & Johnson receives FDA approval to market Palmaz Balloon-expandable Stent for iliac arteries," Business Wire, Oct. 2, 1991.
	C10	"Micellar and Lyotropic Liquid Crystalline Phases Containing Nonionic Active Substances", In: Lyotropic Liquid Crystals and the Structure of Biomembranes, S. Friberg, (ed.), Advances in Chemistry Series, No. 152, American Chemical Society, 28-42, (1976)
	C11	"Muscle-Binding Gene Sees Two-Track Payoff: Human Therapies, Animal Meat", BioWorld Today: The Daily Biotechnology Newspaper, 8(85), Leff, David N., Editor, 1-3, (May 2, 1997)
	C12	"Prevention of Coronary Heart Disease", In: Avery's Drug Treatment — Principles and Practice of Clinical Pharmacology and Therapeutics, Speight, T. M., (ed.), Williams and Wilkins, Baltimore, 594-595, (1987)
	C13	"Quantikine – Human TGFβ ₁ Immunoassay", Product Brochure, Catalog No. DB100, R&D Systems, Inc., p. 1-19,
	C14	"Schering/Orion Fareston Anti-Estrogen for Treatment of Metastatic Breast Cancer 'Similar' to Tamoxifen, FDA Oncologic Committee Says in Approval Vote", F-D-C Reports, 15-16, (Oct. 23, 1995)
	C15	"Shiga Medical Center for Adult Diseases, "The Impact of Tranilast on Restenosis Following Coronary Angioplasty: The Tranilast Restenosis Following Angioplasty Trial (TREAT)", Circulation, 90, 1-82, Abstract No. 0, (October 1988)
	C16	"Tamoxifen therapy found safe for survivors of breast cancer", Fred Hutchinson Cancer Research Center Newsletter, 1(21), (October 1995)
	C17	"Toprol XL TM Tablets", In: Physician's Desk Reference., 658-660, (Probably 1992)
	C18	Agarwal, A.K., et al., "Estrogen Receptor-Binding Affinity of Tamoxifen Analogs with Various Side Chains and their Biologic Profile in Immature Rat Uterus", Steroids, 56, 486-489, (1991)
	C19	AinMelk, Y., et al., "Tamoxifen Citrate Therapy in Male Fertility", Fertility and Sterility, 48, 113-117, (July 1987)
	C20	Alberts, B. et al., "Molecular Biology of the Cell" 2 nd edition 1989, p653
	C21	Alberts, B., et al., "Actin Filaments are Continually Formed and Broken Down in Cells", In: Molecular Biology of the Cell, Garland Publishing, London, 571, (1983)
	C22	Alderson, T. 1990.. "New targets for cancer chemotherapy – poly(ADP-ribosylation) processing and polyisoprenic metabolism," Biol. Rev. 65:623-641
	C23	Aldridge, D.C., et al., "The Structures of Cytochalasins A and B", J. Chem. Soc., 17, 1667-1676, (1967)
	C24	Alich, A.A., et al., "Comparison of Aspirin and Copper Aspirinate with Respect to Gastric Mucosal Damage in the Rat", Journal of Pharmaceutical Sciences, 72, 1457-1461, (Dec. 1983)
	C25	Alich, A.A., et al., "Gastric Mucosal Damage Due to Aspirin and Copper Aspirinate Assessed by Gastric Mucosal Potential Difference Changes", Journal of Pharmacological and Toxicological Methods, 27, 245-250, (Jul. 1992)
	C26	Alich, A.A., et al., "Response to: 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", Journal of Pharmaceutical Sciences, 73, Open Forum, 1876-1877, (Dec. 1984)
	C27	Allemann, et al., "Distribution, Kinetics, and Elimination of Radioactivity after Intravenous and Intramuscular Injection of 14C-Savoxepoie Loaded Poly (D,L-lactic acid) Nanospheres to Rats", J. Controlled Release, 29, 97-104, (1994)
	C28	Allen, K.E., et al., "Evidence For The Metabolic Activation of Non-Steroidal Antioestrogens: A Study of Structure-Activity Relationships", Br.J. Pharmac., 71, 83-91, (1980)
	C29	Allen, R.E. & Boxhor, L.K. "Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta," J Cell. Physiol. 133:567-572.(1987)
	C30	Allgemeine und spezielle Pharmakologie und Toxikologie, by W. Forth et al. 1984, pages 524-531 and 627-633
	C31	Alvarado, et al. "Evaluation of Polymer-Coated Balloon Expandable Stents in Bile Ducts," Radiology 165 (suppl.):33 1 (1987)
	C32	Anderson et al., "Restenosis after coronary angioplasty," J. Interv. Cardiol., 6(3)187-202 (1993)
	C33	Ando et al., "Chimeric DNA-RNA hammerhead ribozyme targeting transforming growth factor-beta 1 mRNA inhibits neointima formation in rat carotid artery after balloon injury", Eur. J. Pharmacol., 438:207-14 (2004)
	C34	Anker, et al., "Plasma Levels of the Atherogenic Amino Acid Homocysteine in Post-Menopausal Women with Breast Cancer Treated with Tamoxifen", Int. J. Cancer, 60, 365-368, (1995)
	C35	Arao, Y., et al., "A synthetic oestrogen antagonist, tamoxifen, inhibits oestrogen-induced transcriptional, but not post-transcriptional, regulation of gene expression", Biochem. J., 313, 269-274, (1996)
	C36	Askelband et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts," Transplantation Proceedings, 23 2833-2836 (1991)
	C37	Assoian et al., "Transforming growth factor-beta in human platelets: identification of a major storage site, purification, and characterization", J. Biol. Chem. 258:7155-7160 (1983)

	C38	Assoian, R.K., et al., "Cellular Transformation by Coordinated Action of Three Peptide Growth Factors from Human Platelets", <i>Nature</i> , 309, 804-806, (June 28, 1984)
	C39	Babaev, et al., "Heterogeneity of smooth muscle cells in atheromatous plaques of human aorta," <i>Am J. Pathol.</i> 136:1031- 1042. (1990)
	C40	Bailey <i>et al.</i> , "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after stent placement." <i>Circulation</i> 82:III-541 (1990)
	C41	Baim, D.S., et al., "Nonatherosclerotic Coronary Heart Disease", In: <i>The Heart: Arteries and Veins</i> , Sixth Edition, Logue, R.B., et al., (eds.), McGraw-Hill Book Company, New York, 1016-1025, (1986)
	C42	Bang, H.O., et al., "The Composition of the Eskimo Food in North Western Greenland", <i>Am. J. Clin. Nutr.</i> , 33, 2657-2661, (1980)
	C43	Baqual, J.G., et al., "Down-Regulation of NADPH-Diaphorase (Nitric Oxide Synthase) May Account for the Pharmacological Activities of Cu(II)sub2(3,5-Diisopropylsalicylate)sub4., <i>J. Inorganic Biochem.</i> , 60, 133-148, (1995)
	C44	Baral, E., et al., "Modulation of Lymphokine-Activated Killer Cell-Mediated Cytotoxicity By Estradiol and Tamoxifen", <i>Int. J. Cancer</i> , 66, 214-218, (1996)
	C45	Barbucci, et al., Coating of Commercially available materials with a new heparinizable material, 1991, pp. 1259-1274
	C46	Baringa, "Gene Therapy for Clogged Arteries Passes Test in Pigs", <i>Science</i> , 265, 738 (Aug. 5, 1994)
	C47	Barnard, et al., "Regulation of intestinal epithelial cell growth by transforming growth factor-beta." <i>Proc. Natl Acad. Sci. USA</i> 86:1518-1582.(1989)
	C48	Bassing et al., "FKBP12 is not required for the modulation of transforming growth factor beta receptor I signaling activity in embryonic fibroblasts and thymocytes", <i>Cell Growth Differ.</i> , 9(3):223-8 (1998)
	C49	Battegay et al., "TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop", <i>Cell</i> , 63:5t5-524 (1990)
	C50	Baxter Healthcare Corp. Duroflo Biocompatible Treatment
	C51	Beck, L., et al., "Vascular Development: Cellular and Molecular Regulation", <i>The FASEB Journal</i> , 11, 365-373, (1997)
	C52	Benita et al., "Submicron Emulsions as Colloidal Drug Carriers for Intravenous Administration: Comprehensive Physicochemical Characterization", <i>Journal of Pharmaceutical Sciences</i> , 82, (November 1993)
	C53	Bergstrom, Reduction of fibrinogen adsorption on PEG-coated polystyrene surfaces, 1992, p. 779-790, Baxter Healthcare Corp. Duraflo Biocompatible Treatment
	C54	Bernhardt et al., "Acetylsalicylic acid, at high concentrations, inhibits vascular smooth muscle cell proliferation", <i>J. Cardiovasc. Pharmacol.</i> , 21(6):973-6 (1993)
	C55	Berven, L.A., et al., "Cellular Function of p70S6K: A Role in Regulating Cell Motility", <i>Immunology and Cell Biology</i> , 78, 447-451, (2000)
	C56	Bier et al., "Arterial Remodeling: Importance in Primary Versus Restenotic Lesions", <i>JACC</i> , p. 139A, Abstract No. 875-96 (February 1994)
	C57	Billmeyer, F., <i>Textbook of Polymer Science</i> (2d ed.) John Wiley & Sons, Inc. (1971)
	C58	Binmoeller, <i>et al.</i> , "Silicone-Covered Expandable Metallic Stents in the Esophagus: An Experimental Study" <i>Endoscopy</i> 1992; 24:416-20.
	C59	Bittiner, S.B., et al., "A Double-Blind, Randomised, Placebo-Controlled Trial of Fish Oil in Psoriasis", <i>The Lancet</i> , 1, 378-380, (Feb. 20, 1988)
	C60	Bjorkerud, "Effects of transforming growth factor-beta1 on human arterial smooth muscle cells in vitro", <i>Arterioscler. Thromb.</i> , 11(4):892-902 (1991)
	C61	Block, P.C. "Coronary-artery stents and other endoluminal devices," <i>New Engl.J.Med.</i> 1991; 324-52-3
	C62	Bluming, "Hormone Replacement Therapy: Benefits and Risks for the General Postmenopausal Female Population and for Women with a History of Previously Treated Breast Cancer", <i>Seminars in Oncology</i> , 20, 662-674, (December 1993)
	C63	Bohmova et al., "Effect of sirolimus on ischemia/reperfusion injury in transgenic hypertensive rat", <i>Transplant Proc.</i> , 34(8):3051-3052 (2002)
	C64	Border, W.A., et al., "Targeting TGF-Beta for Treatment of Disease", <i>Nature Medicine</i> , 1(10), 1000-1001, (October 1995)
	C65	Boscoboinik et al., "Alpha-tocopherol (vitamin E) regulates vascular smooth muscle cell proliferation and protein kinase C activity", <i>Arch. Biochem. Biophys.</i> , 286(1):264-9 (1991)
	C66	Boyle, "Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture", <i>Curr. Vasc. Pharmacol.</i> , 3(1):63-8 (2005)
	C67	Brand, C., et al., "Transforming Growth Factor Beta1 Decreases Cholesterol Supply to Mitochondria via Repression of Steroidogenic Acute Regulatory Protein Expression", <i>The Journal of Biochemistry</i> , 273(11), 6410-6416, (1998)
	C68	Braun-Dullaues et al., "Cell cycle protein expression in vascular smooth muscle cells in vitro and in vivo is regulated through phosphatidylinositol 3-kinase and mammalian target of rapamycin", <i>Arterioscler Thromb Vasc Biol.</i> 21(7):1152-58 (2001)

C69	Brem et al., "Polymers as Controlled Drug Delivery Devices for the Treatment of Malignant Brain Tumours." European Journal of Pharmaceuticals and Biopharmaceutics, 1993, Vol, 39, No. 1, pp 2-7
C70	Brody, J.E., "Study Finds New Estrogen Offers Benefit Without Risk", The New York Times, A32, (December 4, 1997)
C71	Brott et al., "Vessel Remodeling After Angioplasty: Comparative Anatomic Studies", JACC, p. 138A, Abstract No. 875-43 (February 1994)
C72	Burr, M.L., et al., "Effects of Changes in Fat, Fish and fibre Intakes on Death and Myocardial Reinfarction: Diet and Reinfarction Trial (DART)", The Lancet, 757-761, (Sep. 30, 1989)
C73	Burton, T.M., "Lilly Osteoporosis Treatment Shows Promise", The Wall Street Journal, p. A3, A6, (June 6, 1997)
C74	C. Chamsangavej et al., A New Expandable Metallic Stent for Dilation of Stenotic Tubular Structures: Experimental and Clinical Evaluation, Houston Medical Journal 1987;2:41-51 ..
C75	C. T. Dotter, "Transluminally Placed Coil Spring Endarterial Tube Grafts Long Term Patency in Canine Popliteal Arteries," Investigative Radiology 1969;4:329- 332.
C76	Calver et al. "Intracoronary Multi-link stents: experience in 218 patients using aspirin alone," Heart 1998;80:499-504
C77	Camenzind, et al., "Use of Locally Delivered Conventional Drug Therapies", Semin. Intervent. Cardiol., 1, 67-76 (1996)
C78	Cannon, M., et al., "Competition Between Trichodermin and Several Other Sesquiterpene Antibiotics for Binding to their Receptor Site(s) on Eukaryotic Ribosomes", Biochem. J., 160, 137-145, (1976)
C79	Castellot et al., "Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth", J. Cell Biol., 90:372-379 (1981)
C80	Castellot et al., "Effect of heparin on vascular smooth muscle cells. I. Cell metabolism", J. Cell. Physiol., 124:21-28 (1985)
C81	Castellot et al., Heparin selectively inhibits a protein kinase c-dependent mechanism of cell cycle progression in calf aortic smooth muscle cells, J Cell Biol., 109:3147-3155 (1989)
C82	Chamberlain, "Transforming growth factor-beta: a promising target for anti-stenosis therapy", Cardiovasc. Drug Rev., 19(4):329-344 (2001)
C83	Chamley-Campbell and Campbell, "What controls smooth muscle phenotype?", Atherosclerosis, 40:347-357 (1981)
C84	Chamsangavej et al., "Endovascular Stent for Vena Caval Stenosis: Laboratory Experiment and Potential Clinical Applications," Radiology 1985 Nov;157(P):66 Abs. 129.
C85	Chandrasekar, B., et al., "Dietary Omega-3 Lipids Delay the Onset and Progression of Autoimmune Lupus Nephritis by Inhibiting Transforming Growth Factor Beta mRNA and Protein Expression", Journal of Autoimmunity, 8, 381-393, (1995)
C86	Chandy, T., et al., "Chitosan Matrix for Oral Sustained Delivery of Ampicillin", Biomaterials, 14, 939-944, (1993)
C87	Chang, M.P., et al., "Comparison of the Intoxication Pathways of Tumor Necrosis Factor and Diphtheria Toxin", Infection and Immunity, 58, 2644-2650, (Aug., 1990)
C88	Charles Dotter et al., "Transluminally Treatment of Arteriosclerotic Obstruction Description of a New Technique and a Preliminary Report of its Application," Circulation 1964;30:654-669
C89	Charlier, C., et al., "Tamoxifen and Its Active Metabolite Inhibit Growth of Estrogen Receptor-Negative MDA-MB-435 cells", Biochemical Pharmacology, 49(3), 351-358, (January 1995)
C90	Charlier, et al., "Tamoxifen in the Treatment of Breast Cancer", J. Gynecol. Obstet Biol. Reprod., 23, 751-756, (1994)
C91	Chamsangavej, et al., "Stenosis of the Vena Cava: Preliminary Assessment of Treatment with Expandable Metallic Stents," Radiology 1986 Nov;161:295.
C92	Chauhan et al., "Activation of Transforming Growth Factor-B is Inversely Correlated with Three Major Risk Factors for Coronary Artery Disease: Lipoprotein(a), LDL-Cholesterol and Plasminogen Activator Inhibitor-1", Circulation, 90 1-623, Abstract No. 3354 (October 1994)
C93	Cheitlin, M.D., et al., "Myocardial Infarction without Atherosclerosis", JAMA, 231, 951-959, (1975)
C94	Chen et al., "Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells", Proc. Natl. Acad. Sci., 84:5287-5291 (1987)
C95	Clark, D.A., et al., "Coronary Artery Spasm: Medical Management, Surgical Denegation, and Autotransplantation", The Journal of Thoracic and Cardiovascular Surgery, 73, 332-339, (1977)
C96	Clarke, S.C., et al., "Tolerance and Responses To Tamoxifen and Toremifene in Male Patients with Coronary Artery Disease.", Abstract for ACC Meeting, March 1999
C97	Clinton, S.K., "Induction in vivo of Interleukin-1 (IL-1) Gene Expression in Rabbit Aortic Tissue", Abstracts of the 61st Scientific Sessions, II-65
C98	Clowes and Kamowsky, "Suppression by heparin of smooth muscle cell proliferation in injured arteries", Nature, 265:625-626 (1977)
C99	Clowes et al., "Heparin and cilazapril together inhibit injury-induced intimal hyperplasia", Hypertension, 18:II-65-II-69 (1991)
C100	Colletta, A.A. et al., "Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts", Br. J. Cancer, 62, 405-409, (1990)
C101	Columbo et al., "A Novel Strategy for Stent Deployment in the Treatment of Acute or Threatened Closure

		Complicating Balloon Coronary Angioplasty," JACC 1993 Dec;22(7):1887-91,
	C102	Comezoglu, F.T. et al., "Serum Stability and Cytotoxicity of the Macrocyclic Trichothecenes Roridin A, Verrucaridin A and Their Monoclonal Antibody Conjugates", Proceedings of the American Association for Cancer Research, 31, Abstract No. 1723, p. 291, (Mar., 1990)
	C103	Coombes, R.C., et al., "Idoxifene: Report of a Phase I Study in Patients with Metastatic Breast Cancer", Cancer Research, 55, 1070-1074, (Mar. 1, 1995)
	C104	Corcos, et al., "Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty", Am. Heart J., 109(5):926-931 (1985)
	C105	Cotton, P., "Restenosis Trials Suggest Role for Remodeling", JAMA, 271, 1302-1305, (May 4, 1994)
	C106	Craig et al., "Anticoagulant Drugs" in Modern Pharmacology; Little, Brown & Co.: Boston; p. 399 (1982)
	C107	Csernok, E., et al., "Transforming Growth Factor-beta (TGF-beta) Expression and Interaction with Proteinase 3 (PR3) in Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis", Clin. Exp. Immunol., 105, 104-111, (1996)
	C108	Cunningham, A., et al., "A Study of the Structural Basis of the Carcinogenicity of Tamoxifen, Toremifene and their Metabolites", Mutation Research, 349, 85-94, (1996)
	C109	Currier et al., "Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit", J. Am. Coll. Cardiol., 17(6):118B-125B (1991)
	C110	Currier, "Restenosis After Percutaneous Transluminal Coronary Angioplasty: Have We Been Aiming at the Wrong Target?", JACC, 25 516-520 (February 1995)
	C111	Dangas, G., et al., "Management of Restenosis after Coronary Intervention", American Heart Journal, 132, 428-436, (1996)
	C112	Davies, A.M., et al., "Peroxidase Activation of Tamoxifen and Toremifene Resulting in DNA Damage and Covalently Bound Protein Adducts", Carcinogenesis, 16, 539-545, (1995)
	C113	deAlvarez, L.R., et al., "Mechanism of Superoxide Anion Scavenging Reaction by Bis-(Salicylate)-Copper(II) Complex", Biochemical and Biophysical Research Communications, 69, 687-694, (1976)
	C114	Dehmer, G.J., et al., "Reduction in the Rate of Early Restenosis After Coronary Angioplasty by a Diet Supplemented with n-3 Fatty Acids", N. Engl. J. Med., 319, 733-740, (1988)
	C115	Del Vecchio et al., "Inhibition of human scleral fibroblast proliferation with heparin, Invest". Ophthalmol. Vis. Sci., 29:1272-1276 (1988)
	C116	Delmas, P.D., "Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women", The New England Journal of Medicine, 337(23), (1997)
	C117	Dennis E. Chenoweth, Complement Activation in Extracorporeal Circuits, pp. 306-329
	C118	DiGiacomo, R.A., et al., "Fish-Oil Dietary Supplementation in Patients with Raynaud's Phenomenon: A Double-Blind, Controlled, Prospective Study", Am. J. Med., 86, 158-164, (Feb. 1989)
	C119	DiLuccio, R.C., et al., "Sustained-Release Oral Delivery of Theophylline by Use of Polyvinyl Alcohol and Polyvinyl Alcohol-Methyl Acrylate Polymers", Journal of Pharmaceutical Sciences, 83, 104-106, (January 1994)
	C120	DiMario, "Is the Mechanism of Restenosis Device-Independent? Serial Assessment with Intracoronary Ultrasound", Circulation, 90, I-24, Abstract 115 (October 1994)
	C121	Donnelly, J., et al., "Protective Efficacy of Intramuscular Immunization with Naked DNA; DNA Vaccines: A New Era in Vaccinology, Margaret A. Liu et al., eds.", Annals of the New York Academy of Sciences, 772, 40-44, (1995)
	C122	Dotter, "Intraventional Radiology - Review of an Emerging Field," Seminars In Roentgenology 1982;16(1):7-8,
	C123	Dove, C.R., et al., "Effect of Vitamin E and Copper on the Vitamin E Status and Performance of Growing Pigs", J. Anim. Sci., 69, 2516-2523, (1991)
	C124	Dowsett, M., "New Developments in the Hormonal Treatment of Breast Cancer", In: The Treatment of Cancer: Beyond Chemotherapy, Conference Documentation, The Gloucester Hotel, London, 7 p., (Mar. 13-14, 1995)
	C125	Dragan, Y.P., et al., "Comparison of the Effects of Tamoxifen and Toremifene on Liver and Kidney Tumor Promotion in Female Rats", Carcinogenesis, 16, 2733-2741, (1995)
	C126	Draper, M.W., et al., "Antiestrogenic Properties of Raloxifene", Pharmacology, 50, 209-217, (April 1995)
	C127	Dyerberg, J., "Platelet--Vessel Wall Interaction: Influence of Diet", Phil. Trans. R. Soc. Lond., B 294, 372-381, (1981)
	C128	Dyerberg, J., et al., "The Effect of Arachidonic- and Eicosapentaenoic Acid on the Synthesis of Prostacyclin-like Material in Human Umbilical Vasculature", Artery, 8, 12-17, (1980)
	C129	Edelman, E.R., et al., "Effect of Controlled Adventitial Heparin Delivery on Smooth Muscle Cell Proliferation Following Endothelial Injury", Proc. Natl. Acad. Sci. USA, 87, 3773-3777, (May, 1990)
	C130	Ellis et al., "Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty", Am. Heart J., 117(4):777-782 (1989)
	C131	Ellis, S.G., et al., "In-Hospital Cost of Percutaneous Coronary Revascularization: Critical Determinants and Implications", Circulation, 92, 741-747, (1995)
	C132	Endres, S., et al., "The Effect of Dietary Supplementation with n-3 polyunsaturated Fatty Acids on the Synthesis of Interleukin-1 and Tumor Necrosis Factor by Mononuclear Cells", N. Engl. J. Med., 320, 265-271, (1989)

	C133	Esnouf, M.P., et al., "The Inhibition of the Vitamin K-Dependent Carboxylation of Glutamyl Residues in Prothombin by Some Copper Complexes", FEBS Letters, 107, 146-150, (1979)
	C134	Espinosa, E., et al., "17-Estradiol and Smooth Muscle Cell Proliferation in Aortic Cells of Male and Female Rats", Biochemical and Biophysical Research Communication, 221, 8-14, (1996)
	C135	Evans, G.L., et al., "Tissue-Selective Actions of Estrogen Analogs", Bone, 17, 181S-190S, (October 1995)
	C136	Faxon et al., "Enozaprain, a low molecular weight heparin, in the prevention of restenosis after angioplasty: results of a double blind randomized trial", JACC 19:258A, Abstract 783-3 (1992)
	C137	Ferrari, R.P., et al., "Changes of Serum Iron Transferrin and Copper Ceruloplasmin in Rats Given Cu(II) sub2 (Acetylsalicylate) sub4 During Acute Inflammation", Anticancer Res., 9, 771-774, (1989)
	C138	Fett-Neto, A.G., et al., "Effect of White Light on Taxol and Baccatin III Accumulation in Cell Cultures of Taxus Cuspidata Sieb and Zucc.", J. Plant Physiol., 146, 584-590, (1995)
	C139	Fischell, et al., "Low-Dose, beta-Particle Emission From 'Stent' Wire Results in Complete, Localize Inhibition of Smooth Muscle Cell Proliferation", Circulation, 90 2956-2963 (December, 1994)
	C140	Fischman, et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease: The New England Journal of Medicine, 331, 496-501 (August, 1994)
	C141	Fisher, M., et al., "Dietary n-3 Fatty Acid Supplementation Reduces Superoxide Production and Chemiluminescence in a Monocyte-Enriched Preparation of Leukocytes", Am. J. Clin. Nutr., 51, 804-808, (1990)
	C142	Flanders, K.C., et al., "Altered Expression of Transforming Growth Factor-B in Alzheimer's Disease", Neurology, 45, 1561-1569, (August 1995)
	C143	Flanders, K.C., et al., "Transforming Growth Factor-B1: Histochemical Localization With Antibodies to Different Epitopes", Journal of Cell Biology, 108, 653-660, (Feb. 1989)
	C144	Foekens, J.A., et al., "Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1: Predictors of Poor Response to Tamoxifen Therapy in Recurrent Breast Cancer", Journal of the National Cancer Institute, 87(10), 751-756, (May 1995)
	C145	Forney-Prescott et al., "Angiotensin-converting enzyme inhibito' versus angiotensin II, AT1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury", Am J Pathol, 139:1291-1296 (1991)
	C146	Fox and DiCorleto, "Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein", Science, 241 (4864):453-456 (1988)
	C147	Frautschy, S.A., et al., "Rodent Models of Alzheimer's Disease: Rat A Infusion Approaches to Amyloid Deposits", Neurobiology of Aging, 17, 311-321, (1996)
	C148	Frazier-Jessen, et al., "Estrogen Modulation of JE/Monocyte Chemoattractant Protein-1 mRNA Expression in Murine Macrophages", J. Immunol., 1828-1845
	C149	Frye, L.L., et al., "Oxolanosterol Oximes: Dual-Action Inhibitors of Cholesterol Biosynthesis", Journal of Lipid Research, 35, 11333-1344, (1994)
	C150	Fukaura, H., et al., "Induction of Circulating Myelin Basic Protein and Proteolipid Protein-Specific Transforming Growth Factor- B1-secreting Th3 T Cells by Oral Administration of Myelin in Multiple Sclerosis Patients", J. Clin. Invest., 98, 70-77, (1996)
	C151	Fukuda, et al., "Distinct Expression of Transforming Growth Factor-B Receptor Subtypes on Vascular Smooth Muscle Cells from Spontaneously Hypertensive Rats and Wistar-Kyoto Rats", Clin. Exp. Pharmacol. Physiol. Supply., 1, S120, 1995
	C152	Furr, B.J., et al., "The Pharmacology and Clinical Uses of Tamoxifen", Pharmac. Ther., 25, 127-205, (1984)
	C153	Gebhardt, R., et al., "Differential Inhibitory Effects of Garlic-Derived Organosulfur Compounds on Cholesterol Biosynthesis in Primary Rat Hepatocyte Cultures", Lipids, 31, 1269-1276, (1996)
	C154	Gebhardt, R., et al., "Inhibition of Cholesterol Biosynthesis by Allicin and Ajoene in Rat Hepatocytes and HepG2 Cells", Biochimica et Biophysica Acta, 1213, 57-62, (1994)
	C155	Gertz et al., "Geometric Remodeling Is Not the Principal Pathogenic Process in Restoenosis After Balloon Angioplasty", Circulation, 90, 3001-3008 (December 1994)
	C156	Giachelli, et al., "Osteopontin is Elevated During Neointima Formation in Rat Arteries and is a Novel Component of Human Atherosclerosis Plaques", J. Clin. Invest., 92, 1686-1696, (Oct. 1993)
	C157	Gibbons et al., "The emerging concept of vascular remodeling", New Engl. J. of Medicine, 330 1431-1437 (1994)
	C158	Gibson, D.M., et al., "Initiation and Growth of Cell Lines of Taxus Brevifolia (Pacific Yew)", Plant Cell Reports, 12, 479-482, (1993)
	C159	Glagov, S., "Intimal Hyperplasia, Vascular Modeling, and the Restenosis Problem", Circulation, 89, 2888-2891, (1994)
	C160	Gradishar, W.J., et al., "Clinical Potential of New Antiestrogens", Journal of Clinical Oncology, 15, 840-852, (1997)
	C161	Graham et al., "Dexamethasone Inhibits Grown and Na:H Exchange in Vascular Smooth Muscle Cells" Journal of Endocrinology, 129 (Suppl.) Abstract 180, 10 th Joint Metting of British Endocrine Societies, Brighton, England, UK, April 15-18, (1991)
	C162	Grainger and Metcalfe, "Transforming growth factor-β and cardiovascular protection, draft"(NeoRx 019151-019213)
	C163	Grainger and Metcalfe, TGF-beta: implications for human vascular disease. J Hum Hypertens., 9(8):679 (1995)

	C164	Grainger and Mosedale, "TGF- β and the cardiovascular system, TGF- β and Related Cytokines in Inflammation," Breit, SN and Wahl, SM (ed.), Birkhauser Verlag, 91-146 (2001) (DJG 006134-006190).
	C165	Grainger et al., "Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions", J. Cell Sci., 113:2355-2361(2000)
	C166	Grainger et al., "Red wine, but not white wine, elevates circulating TGF- β levels -possible role of a salicylate complex," DJG 003915-003920.
	C167	Grainger et al., "Transforming growth factor-beta dynamically regulates vascular smooth muscle cell differentiation in vivo", J. Cell Sci., 111:2977-2988 (1998)
	C168	Grainger, D.J., "Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis", Arterioscler. Thromb. Vasc. Biol., 24:399-404 (2004) (DJG 006208-006213)
	C169	Grainger, D.J., et al., "A Pivotal Role for TGF-Beta in Atherogenesis?", Biol. Rev., 70, 571-596, (1995)
	C170	Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited by Apolipoprotein (a) in vivo", Circulation, 90, 67 th Scientific Session, Abstract No. 3353, p. I-623, (Oct., 1994)
	C171	Grainger, D.J., et al., "Activation of Transforming Growth Factor-beta is Inhibited in Transgenic Apolipoprotein (a) Mice", Nature, 370 460-462, (Aug. 11, 1994)
	C172	Grainger, D.J., et al., "Active and Acid-Activatable TGF-beta in Human Sera, Platelets and Plasma", Clinica Chimica Acta., 235, 11-31, (Feb., 1995)
	C173	Grainger, D.J., et al., "Active TGF-beta is Depressed Five-fold in Triple Vessel Disease Patients Compared with Syndrome X Patients", Journal of Cellular Biochemistry, 18A, Abstract No. E111, p. 267, (1994)
	C174	Grainger, D.J., et al., "Active Transforming Growth Factor-beta is Depressed in Patients with Three Vessel Coronary Artery Disease", Circulation, 90, 67 th Scientific Sessions, Abstract No. 2754, p. I-512, (Oct., 1994)
	C175	Grainger, D.J., et al., "Mitogens for Adult Rat Aortic Vascular Smooth Muscle Cells in Serum-Free Primary Culture", Cardiovascular Research, 28, 1238-1242, (1994)
	C176	Grainger, D.J., et al., "Proliferation of Human Smooth Muscle Cells Promoted by Lipoprotein(a)", Science, 260, 1655-1658, (June 11, 1993)
	C177	Grainger, D.J., et al., "Release and Activation of Platelet Latent TGF-Beta in Blood Clots During Dissolution with Plasmin", Nature Medicine, 1, 932-937, (1995)
	C178	Grainger, D.J., et al., "Tamoxifen Elevates Transforming Growth Factor-beta and Suppresses Diet-Induced Formation of Lipid Lesions in Mouse Aorta", Nature Medicine, 1, 1067-1073, (Oct., 1995)
	C179	Grainger, D.J., et al., "Tamoxifen: Teaching an Old Drug New Tricks?", Nature Medicine, 2, 381-385, (Apr., 1996)
	C180	Grainger, D.J., et al., "The Serum Concentration of Active Transforming Growth Factor-beta is Severely Depressed in Advanced Atherosclerosis", Nature Medicine, 1, 74-80, (Jan., 1995)
	C181	Grainger, D.J., et al., "Transforming Growth Factor beta Decreases the Rate of Proliferation of Rat Vascular Smooth Muscle Cells by Extending the G2 Phase of the Cell Cycle and Delays the Rise in Cyclic AMP Before Entry into M Phase", Biochemical Journal, 299, 227-235, (1994)
	C182	Grainger, D.J., et al., "Transforming Growth Factor-beta and Cardiovascular Protection", In: The Endothelium in Clinical Practice, Rubanyi, G.M., et al., (eds.), Marcel Dekker, Inc., New York, 203-243, (1997)
	C183	Grainger, D.J., et al., "Transforming Growth Factor-beta is Sequestered into an Inactive Pool by Lipoproteins", Journal of Lipid Research, 38, 117-125, (1997)
	C184	Grainger, D.J., et al., "Transforming Growth Factor-beta: The Key to Understanding Lipoprotein(a)?", Current Opinion In Lipidology, 6, 81-85, (1995)
	C185	Grainger, D.J., University of Cambridge Ph.D. Thesis, Control of the proliferation and differentiation of vascular smooth muscle cells, DJG 005911-006102 (1992) and all references therein
	C186	Gravlee, G.P. MD, Heparin-Coated Cardiopulmonary Bypass Circuits, Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, April 1994, pp. 213-222
	C187	Gref, et al., "Biodegradable Long-Circulating Polymeric Nanoshells", Science, 263, 1600-1603, (March 18, 1994)
	C188	Gregory et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury", Transplantation, 55 1409-1418 (1993)
	C189	Gregory et al., "Treatment with rapamycin blocks arterial intimal thickening following mechanical and alloimmune injury", Transplant. Proc., 25:120-21 (1993)
	C190	Grese, T.A., et al., "Structure-Activity Relationships of Selective Estrogen Receptor Modulators: Modification to the 2-Arylbenzothiophene Core of Raloxifene", J. Med. Chem., 40, 146-167, (1997)
	C191	Grey, A.B., et al., "The Effect of the Anti-Estrogen Tamoxifen on Cardiovascular Risk Factors in Normal Postmenopausal Women", J. Clinical Endocrinology and Metabolism, 80, 3191-3195, (1995)
	C192	Grigg, L.E., et al., "Determinants of Restenosis and Lack of Effect of Dietary Supplementation with Eicosapentaenoic Acid on the Incidence of Coronary Artery Restenosis After Angioplasty", JACC, 13, 655-672, (1989)
	C193	Gruntzig, et al., "Nonoperative Dilatation of Coronary-Artery Stenosis," New England J. Med.. 1979 Jul 12;301(2):61-68.
	C194	Guba et al., "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor", Nat. Med., 8(2):128-35 (2002)
	C195	Guetta, V., et al., "Effects of the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations and Oxidation in Postmenopausal Women", The American Journal of Cardiology, 76, 1072-1073, (November 15,

		1995)
	C196	Gulino, A., et al., "Heterogeneity of Binding Sites for Tamoxifen and Tamoxifen Derivatives in Estrogen Target and Nontarget Fetal Organs of Guinea Pig, Cancer Research 42, 1913-1921, (May 1982)
	C197	Guyton et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vivo studies with anticoagulant and noncoagulant heparin", Circ. Res., 46(5):625-634 (1980)
	C198	Gylling, H., et al., "Tamoxifen and Toremifene Lower Serum Cholesterol by Inhibition of Delta8-Cholesterol Conversion to Lathosterol in Women with Breast Cancer", Journal of Clinical Oncology, 13, 2900-2905, (1995)
	C199	Gylling, H., et al., "Tamoxifen Decreases Serum Cholesterol by Inhibiting Cholesterol Synthesis", Atherosclerosis, 96, 245-247, (1992)
	C200	Hafzi et al., "Differential effects of rapamycin, cyclosporine A, and FK506 on human coronary artery smooth muscle cell proliferation and signalling", Vascu. Pharmacol., 41:167-76 (2004)
	C201	Hahn, L., et al., "The Influence of Acetylsalicylic Acid and Paracetamol on Menstrual Blood Loss in Woman With and Without an Intrauterine Contraceptive Device", Am. J. Obstet. Gynecol., 135, 393-396, (1979)
	C202	Hall, I.H., et al., "Hypolipidemic Activity of Tetrakis-mu-(trimethylamine-boranecarboxylato)-bis (trimethylamine-carboxyborane) -dicopper (II) in Rodents and Its Effect on Lipid Metabolism", J. Pharmaceut. Sci., 73, 973-977, (1984)
	C203	Hanson, et al., "In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis, "J. Lab. Clin. Med. 95:289-304; 1980
	C204	Hanson, et al., "Testing of Blood – Materials Interactions," Biomaterials Science (B.D. Ratner, Ed.), Academic Press, 222-238 (1996).
	C205	Hanson, S., "Device Thrombosis and Thromboembolism," Cardiovasc Pathol. 2(3) (Suppl.): 157S-165S (July-Sept. 1993)
	C206	Harpel, et al., "Lp(a) Inhibitor of Plasminogen," Proc. Natl. Acad. Sci. USA, 86, 3847 (1989)
	C207	Harrison, D.C., "Nonatherosclerotic Coronary Artery Disease", In.: Atherosclerosis and Coronary Artery Disease, V. Fuster, et al., (eds.), Lippencott-Raven Publishers, pp. 757-772, (1996)
	C208	Hayden, L.J., "Inhibitors of Gastric Lesion in the Rat", J. Pharm. Pharmac., 30, 244-246, (1978)
	C209	Hayes, D.F., et al., "Randomized Comparison of Tamoxifen and Two Separate Doses of Toremifene in Postmenopausal Patients with Metastatic Breast Cancer", Journal of Clinical Oncology, 13, 2556-2566, (Oct. 1995)
	C210	Hehrlein, C., et al., "Low-Dose Radiactive Endovascular Stents Prevent Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rabbits", Circulation, 92, 1570-1575, (1995)
	C211	Hehrlein, C., et al., "Pure Beta-particle-emitting Stents Inhibit Neointima Formation in Rabbits", Circulation, 93, 641-645, (1996)
	C212	Hermann and Hirshfeld, Jr., "Clinical Use of the Palmaz-Schatz Intracoronary Stent," Futura Publishing Co. (1993).
	C213	Hoffman, A., "Modification of Material Surfaces to Affect How They Interact with Blood, Blood in Contact with Natural and Artificial Surfaces," Leonard, E. et al., (eds), Annals of the New York Academy of Sciences, 516:96-100 (1987)
	C214	Holmes, et al., "Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis", Circulation, 109:634-640 (2004)
	C215	Holmes, Jr., D.R., "Remodeling Versus Smooth Muscle Cell Hyperplasia", Restenosis Summit VI, The Cleveland Clinic Foundation, 222-223, (1994)
	C216	Hoover, et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin:II. In vitro studies", Circ. Res., 47(4):578-83 (1980)
	C217	Hopfenberg, H., "Transport Through Polymers, 7 Encyclopedia of Materials Science and Engineering," (Michael B. Bever, (ed.); The MIT Press, 5141-5145 (1986)
	C218	Howell, A., et al., "New Endocrine Therapies for Breast Cancer", European Journal of Cancer, 32A, 576-588, (1996)
	C219	Hsu, Li-Chien "Principles of Heparin-Coating Techniques", Perfusion 6: 209-219 (1991)
	C220	Huang, et al., "Rapamycins: mechanism of action and cellular resistance." Cancer Biol. Ther., 2(3):222-32 (2003)
	C221	Huang, S.S., et al., "Transforming Growth Factor Beta peptide Antagonists and Their Conversion to Partial Agonists", The Journal of Biological Chemistry, 272(43), 27155-57159, 1997
	C222	Huehns, et al., "Adventitia as a Target for Intravascular Local Drug Delivery", Heart, 75, 437-438 (1996)
	C223	Hughes, D.E., et al., "Estrogen Promotes Apoptosis of Murine Osteoclasts Mediated by TFG-beta", Nature Medicine, 2, 1132-1136, (1996)
	C224	Ishihara, et al., "Synthesis of phospholipid polymers having a urethane bond in the side chain as coating material on segmented polyurethane and their platelet adhesion-resistant properties," Biomaterials, 1995 16(11): 873-879
	C225	Isner, "Vascular Remodeling: Honey, I Think I Shrunk the Artery", Circulation, 89 2937-2841 (June 1994).
	C226	Jacinto and Hall, "Tor signalling in bugs, brain and brawn", Nature Rev. Mol. Cell Biol., 4:117-126 (2003)
	C227	Jande et al., "Effects of cytochalasin B and dihydrocytochalasin B on calcium transport by intestinal absorptive cells", Calcif. Tissue Int. 33, 143-151 (1981); Chem. Abs. 94 Abstract No. 189223e (1981)

	C228	Jeffrey A. Hubbell, Ph.D., "Pharmacologic Modification of Materials" Cardiovasc Pathol Vol2 No.3 (Suppl.) July-Sept. 199,1215-1275
	C229	Jeng, et al., "Regulation of the levels of three transforming growth factor beta mRNAs by estrogen and their effects on the proliferation of human breast cancer cells", Mol. Cell Endocrinol., 92:115-123 (1993)
	C230	Jenkins et al., "Local Delivery of Taxol Inhibits Neointimal Regrowth Following Balloon Injury of the Rat Carotid Artery: , Circulation, 90, p. I-297, Abstract No. 1596 (Oct. 1994)
	C231	Johnston, S.R., et al., "Changes in Estrogen Receptor, Progesterone Receptor, and ps2 Expression in Tamoxifen-resistant Human Breast Cancer", Cancer Research, 55, 3331-3338, (August 1995)
	C232	Jones, R.H., et al., "Increased Susceptibility to Metal Catalysed Oxidation of Diabetic Lens beta subL Crystallin: Possible Protection by Dietary Supplementation with Acetylsalicylic Acid", Exp. Eye Res., 57, 783-790, (1993)
	C233	Jordan, A. et al., "Tubulin as a Target for Anticancer Drugs: Agents which Interact with the Mitotic Spindle", Medicinal Research Reviews, 18, 259-296, (1998)
	C234	Jordan, V.C., et al., "A Mutant Receptor as a Mechanism of Drug Resistance to Tamoxifen Treatment", Annals New York Academy of Science, 761, 138-147, (1995)
	C235	Jordan, V.C., et al., "Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens in Vitro", Molecular Pharmacology, 26, 272-278, (1984)
	C236	Jordan, V.C., et al., "Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer", Annu. Rev. Pharmacol. Toxicol., 35, 195-211, (1995)
	C237	Joswig, B.C., et al., "Transmural Myocardial Infarction in the Absence of Coronary Arterial Luminal Narrowing in a Young Man with Single Coronary Arterial Anomaly", Catheterization and Cardiovascular Diagnosis, 4, 297-304, (1978)
	C238	Kakuta, T., et al., "Differences in Compensatory Vessel Enlargement, Not Intimal Formation, Account for Restenosis After Angioplasty in the Hypercholesterolemic Rabbit Model", Circulation, 89, 2809-2815, (1994)
	C239	Kakuta, T., et al., "The Impact of Arterial Remodeling on the Chronic Lumen Size After Angioplasty in the Atherosclerotic Rabbit", JACC, Abstract No. 875-95, p. 138A, (Feb., 1994)
	C240	Kanzaki, et al., "In vivo effect of TGF-beta1: enhanced intimal thickening by administration of TGF-beta1 in rabbit arteries injured with a balloon catheter", Arterioscler. Thromb. Vasc. Biol., 15(11):1951-57 (1995)
	C241	Kardami et al., "Heparin Inhibits Skeletal Muscle Growth in Vitro", Dev. Biol., 126:19-28 (1988)
	C242	Kariya et al., "Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells". Atherosclerosis, 80:143-147 (1989)
	C243	Kaski, J.C., et al., "Local Coronary Supersensitivity to Diverse Vasoconstrictive Stimuli in Patients with Variant Angina", Circulation, 74, 1255-1265, (1996)
	C244	Kastrati et al., "Restenosis after coronary placement of various stent types," Am. J. Cardiol., 87:34-49 (2001)
	C245	Ke, H.Z., et al., "Comparative Effects of Droloxifene, Tamoxifen, and Estrogen on Bone, Serum Cholesterol, and Uterine Histology in the Ovariectomized Rat Model", Bone, 20, 31-39, (1997)
	C246	Keen, C.L., et al., "Hypertension Induced Alterations in Copper and Zinc Metabolism: A Link to Vascular Disease?", In: Biology of Copper Complexes, Sorenson, J.R.J., (ed.), Humana Press, Clifton, New Jersey, 141-153, (1987)
	C247	Kellen, J.A., "Tamoxifen Beyond the Antiestrogen", Birkhäuser, 392 pages, (1996)
	C248	Kellen, J.A., et al., "The Effect of Toremifene on the Expression of Genes in a Rat Mammary Adenocarcinoma", In Vivo, 10, 511-514, (1996)
	C249	Kemp, P.R., et al., "Cloning and Analysis of the Promoter Region of the Rat SM11-Alpha Gene", Biochem. J., 310, 11043, (1995)
	C250	Kemp, P.R., et al., "Inhibition of PDGF BB Stimulated DNA Synthesis in Rat Aortic Vascular Smooth Muscle Cells by the Expression of a Truncated PDGF Receptor", FEBS Letters, 336, 119-123, (Dec., 1993)
	C251	Kemp, P.R., et al., "ID -- A Dominant Negative Regulator of Skeletal Muscle Differentiation -- is Not Involved in Maturation or Differentiation of Vascular Smooth Muscle Cells", FEBS Letters, 368, 81-86, (1995)
	C252	Kim, et al., "Suppression of Vascular Transforming Growth Factor-B1 and Extracellular Matrix Gene Expressions by Cilazapril and Nifedipine in Hypertensive Rats", Clin. Exp. Pharmacol. Physiol. Suppl., 1, S355, (1995)
	C253	Kim, J. et al., "Production of Taxol and Related Taxanes in Taxus brevifolia Cell Cultures: Effect of Sugar", Biotechnology Letters, 17, 101-106, (Jan., 1995)
	C254	Kingston, D.G., et al., "Synthesis and Structure-Activity Relationships of Taxol Derivatives As Anticancer Agents", In: New Trends in Natural Products Chemistry, Atta-ur-Rahman, et al., (eds.), Studies in Organic Chemistry, Vol. 26, Elsevier Science Publishers B.V., Amsterdam, 219-235, (1986)
	* C255	Kirk-Othmer, Encyclopedia of Chemical Technology, 33 rd edition, Vol. 17, 1982, John Wiley & Sons, pp. 281-310
	C256	Kirschenlohr, H.L., et al., "Cultures of Proliferating Vascular Smooth Muscle Cells from Adult Human Aorta", In: Human Cell Culture, Jones, G.E., (ED.), Humana Press, Inc., 24 p. (1996)
	C257	Kirschenlohr, H.L., et al., "Proliferation of Human Aortic Vascular Smooth Muscle Cells in Culture is Modulated by Active TGF-Beta", Cardiovascular Research, 29, 848-855, (1995)
	C258	Klebe et al., "Regulation of cell motility, morphology, and growth by sulfated glycosaminoglycans", Cell Motil. Cytoskel., 6:273-281 (1986)
	C259	Klein, H.O. et al., "Experimental Investigations on a Sequential Combination Chemotherapy Protocol" J. Cancer Res. Clin. Oncol vol 96 no.2 Jan, 1980 p 65-78

	C260	Kleinman, N.S., et al., "Prinzmetal's Angina during 5-Fluorouracil Chemotherapy", The American Journal of Medicine, 82, 566-568, (1987)
	C261	Knabbe, C., et al., "Induction of Transforming Growth Factor-B by the Antiestrogens Droloxifene, Tamoxifen, and Toremifene in MCF-7 Cells", Am. J. Clin. Oncol. 14, S15-S20, (1991)
	C262	Kopp, A., et al., "Transforming Growth Factor Beta2 (TGF-Beta2) Levels in Plasma of Patients with Metastatic Breast Cancer Treated with Tamoxifen", Cancer Research, 55, 4512-4515, (Oct. 15, 1995)
	C263	Kost, J. Langer R, "Controlled Release of Bioactive Agents," Trends in Biotechnology, Vol. 2, No. 2, 1984, pp. 47-51
	C264	Kotoulas, I.G., et al., "Tamoxifen Treatment in Male Infertility. I. Effect on Spermatozoa", Fertility and Sterility, 61, 911-914, (May 1994)
	C265	Koyama, N., et al., "Regulation of Smooth Muscle Cells Migration by a New Autocrine Migration Factor and TGF-beta", Circulation, 84, Abstract No. 1829, II-459, (1991)
	C266	Kremer, J.M., et al., "Fish-Oil Fatty Acid Supplementation in Active Rheumatoid Arthritis", Annals of Internal Medicine, 106, 497-502, (1987)
	C267	Kunert, et al., "Paclitaxel Inhibits Development of Restenosis Following Experimental Balloon Angioplasty in the Rabbit Carotid Artery", European Heart Journal, 17, Abstract No. P1998, p. 368 (1996)
	C268	Kunz et al., "Defining Coronary Restenosis Newer Clinical and Angiographic Paradigms". Circulation, 88 1310-1323 (September 1993)
	C269	Kunz et al., "Sustained Dilation and Inhibition of Restenosis in a Pig Femoral Artery Injury Model". Circulation, 90, p I-297, Abstract NO. 1598 (October 1994)
	C270	Kunz et al., "Inhibition of Microfilament Reorganization Following Balloon Angioplasty Decreases Extent of Geometric Remodeling in Restenosis", J. of Amer. Coll. of Cardiology, American College of Geometric Cardiology 44 th Annual Scientific Session, Abstract No. 122292. (March 19-22, 1995)
	C271	Kunz, L.L., et al., "Efficacy of Cytochalasin B in Inhibiting Coronary Restenosis Caused by Chronic Remodeling After Balloon Trauma in Swine", Journal of the American College of Cardiology, Supplement A., Abstract No. 984-23, p. 302, (Mar. 1995)
	C272	Kuramochi, H., "Conformational Studies and Electronic Structures of Tamoxifen and Toremifene and Their Allylic Carbocations Proposed as Reactive Intermediates Leading to DNA Adduct Formation", J. Med. Chem., 39, 2877-2886, (1996)
	C273	Kuzana, S., et al., "Effects of Some Anti-Rheumatic Agents on Copper-Catalyzed Thermal Aggregation of Gamma Globulin", Agents and Actions, 9 375-380, (1979)
	C274	L.C. Palmaz et. al., Expandable Intraluminal Graft: A Preliminary Study, Radiology 1985;1:73-77.
	C275	Labhsetwar et al., "Nanoparticles for site specific delivery of U-86983 in restenosis on pig coronary arteries," Proc. Intern. Symp. Control. Rel. Bioact. Mater. 22, 182-183 (1995).
	C276	Laird, J., et al., "Inhibition of Neointimal Proliferation with Low-dose Irradiation from a Beta-particle-emitting Stent", Circulation, 93, 529-536, (1996)
	C277	Langbein, W., "Too Many Drugs, Too Little Value in CV Conditions", In Vivo, 14-20, (June, 1995)
	C278	Lange, R.A., et al., "Cocaine-Induced Coronary-Artery Vasoconstriction", The New England Journal of Medicine, 321, 1557-1562, (1989)
	C279	Lange, R.L., et al., "Nonatheromatous Ischemic Heart Disease following Withdrawal from Chronic Industrial Nitroglycerin Exposure", Circulation, 46, 666-678, (1972)
	C280	Langer, R. et al., "Polymeric Delivery Systems for Macromolecules-Approaches for Studying In Vivo Release Kinetics and Designing Constant Rate Systems", in: <u>Biological Activities of Polymers</u> , Carraher, Jr. and Gebelein (eds), American Chemical Society Symposium Series 186, pp. 95-105 (1982)
	C281	Langer, R. et al., "Polymers for the Sustained Release of Proteins and Other Macromolecules", Nature 263:797-799 (1976)
	* C282	Langer, R., "New Methods of Drug Delivery", Science, Vol. 249, 28.09 1990, pp. 1527-1533
	C283	Langer, R., "Polymeric Delivery Systems for Controlled Drug Release", Chem. Eng. Communi. 6:1-48 (1980)
	C284	Law et al., "Rapamycin potentiates transforming growth factor beta-induced growth arrest in nontransformed, oncogene-transformed, and human cancer cells", Mol. Cell. Biol., 22:8184-8198 (2002)
	C285	Lawn, R.M., et al., "Feedback Mechanism of Focal Vascular Lesion Formation in Transgenic Apolipoprotein(a) Mice", The Journal of Biological Chemistry, 271, 31367-31371, (1996)
	C286	Lazier, C.B., et al., "Comparison of the Effects of Tamoxifen and of a Tamoxifen Analogue that Does Not Bind the Estrogen Receptor on Serum Lipid Profiles in the Cockerel", Biochem. Cell Biol., 68, 210-217, (1990)
	C287	L.C. Palmaz et al., Expandable Intraluminal Vascular Graft: A Feasibility Study, Surgery 1986 Feb; 199(2): 199-205.
	C288	Lehmann, K. et al., "Effect of cilazapril on the proliferative response after vascular damage", J. of Cardiovascular Pharmacology, 22 (Suppl. 4), S19-24, (1993)
	C289	Lehmann-Bruinsma, et al., "Transforming Growth Factor B2 (TGF-B) Suppression of Smooth Muscle Cell (SMC) Proliferation After Balloon Angioplasty of Rat Carotid Arteries", Clin. Res. 42, Abstract No. 4A, (February 9-12, 1994)

	C290	Leroux, J.C., et al., "Internalization of poly(d L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins absorbed onto the particles", J. Biomed. Mater. Res, 28, 471-481, (1994)
	C291	Leroux, et al., "New Approach for the Preparation of Nanoparticles by an Emulsification-Diffusion Method", Eur. J. Pharm. Biopharm, 41, 14-18, (1995)
	C292	Levy, et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants," Chemical Abstracts, 121, 580: Abstract No. 263625g (1994)
	C293	Levy, R.J., et al., "Strategies for Treating Arterial Restenosis Using Polymeric Controlled Release Implants", In: Biotechnology and Bioactive Polymers, Proceedings of an American Chemical Society Symposium, Gebelein, C.G., (ed.), Plenum Press, New York, 259-268, (1994)
	C294	Liau and Chan, "Regulation of extracellular matrix RNA levels in cultured smooth muscle cells: relationship to cellular quiescence", J. Cell Biol., 264:10315-10320 (1989)
	C295	Lichtlen et al., "Retardation of angiographic progression of coronary artery disease by nifedipine", Lancet, 335:1109-1113 (1990)
	C296	Lincoff et al., "Local Drug Delivery for the Prevention of Restenosis" Circulation, 90 2070-2084 (October 1994)
	C297	Lindkaer-Jensen, S., et al., "Inhibition of Salicylate and Lithium Absorption in the Human Intestine by Copper Sulfate", Arch. Toxicol., 35, 175-179, (1976)
	C298	Lindner, "Vascular repair processes mediated by transforming growth factor-beta, Z Kardiol", 90 Suppl 3:17-22 (2001)
*	C299	Lipold, B.C., "Retardarzneiformen" in E. Numberg, Hagers Handbuch der pharmazeutischen Praxis, Vol. 2, Springer-Verlag Berlin Heidelberg New York, 5 th edition, 1991 pp. 832-840
	C300	Lippman and Mathews, "Heparins: varying effects on cell proliferation in vitro and lack of correlation with anticoagulant activity", Fed. Proc., 36:55-59 (1977)
	C301	Liu et al., "Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit", Circulation, 81(3): 1089-1093 (1990)
	C302	Lopez-Anaya, A., et al., "Pharmacokinetics and Pharmacodynamics in Copper Deficiency I", Biological Trace Element Research, 40, 161-176, (1994)
	C303	Lopez-Casillas, et al., "Beta-glycan Presents Ligand to the TGFβ Signaling Receptor", Cell, 73, 1435-1444, (July 2, 1993)
	C304	Loser, R., et al., "In Vivo and in Vitro Antiestrogenic Action of 3-Hydroxytamoxifen, Tamoxifen and 4-Hydroxytamoxifen", Eur. J. Cancer Clin. Oncol., 21, 985-990, (1985)
	C305	Lowe, et al., "Coronary In-Stent Restenosis: Current Status and Future Strategies", Journal of the American College of Cardiology, 1992, Vol. 39 No. 2, pp. 183-193.
	C306	Luan et al., "Rapamycin is an effective inhibitor of human renal cancer metastasis", Kidney Int., 63:917-926 (2003)
	C307	Lucas, C., et al., "The Authocrine Production of Transforming Growth Factor-β1 During Lymphocyte Activation", The Journal of Immunology, 145(5), 1415-1422, (1990)
	C308	Ludwig K. von Segesser, MD., "Heparin-Bonded Surfaces in Extracorporeal Membrane Oxygenation for Cardiac Support:, The Society of Thoracic Surgeons, (1996)
	C309	Luo, H. et al., "Chronic Vessel Constriction is an Important Mechanism of Restenosis After Balloon Angioplasty: An Intravascular Ultrasound Analysis", Circulation, 90, 67 Scientific Sessions, Abstract No. 0318, p. I-61, (1994)
	C310	Luostarinen, R., et al., "Effect of Dietary Fish Oil Supplemented with Different Doses of Vitamin E on Neutrophil Chemotaxis in Healthy Volunteers", Nutrition Research, 12, 1419-1430, (1992)
	C311	Lutgens et al., "Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression", Arterioscler. Thromb. Vasc. Biol., 22:975-982 (2002)
	C312	Lyons et al., "Mechanism of activation of latent recombinant transforming growth factor beta1 by plasmin", J. Cell. Biol., 110:1361-1367 (1990)
	C313	Macander et al., "Balloon Angioplasty for Treatment of In-Stent Restenosis: Feasibility, Safety, and Efficacy", Catheterization and Cardiovascular Diagnosis, 32 125-131 (1994)
	C314	Madri et al., "Endothelial cell behavior after denudation injury is modulated by transforming growth factor-beta1 and fibronectin", Lab. Invest., 60:755-764 (1989)
	C315	Magarian, "The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review", Current Medicinal Chemistry, 1, 61-104, (1994)
	C316	Majack, "Beta-type transforming growth factor specifies organizational behavior in vascular smooth muscle cell cultures", J. Cell Biol., 105:465-471 (1987)
	C317	Majack, R.A., et al., "Role of PDGF-A Expression in the Control of Vascular Smooth Muscle Cell Growth by Transforming Growth Factor-β", The Journal of Cell Biology, 111, 239-247, (1990)
	C318	Majesky, M.W., et al., "Production of Transforming Growth Factor beta1 During Repair of Arterial Injury", J. Clin. Invest., 88, 904-910, (1991)
	C319	Mambetisaeva, E.T., et al. "Effect of New Synthetic Cholesterol Derivatives on Cholesterol Metabolism in Cultured Rabbit Hepatocytes", Biokhimiya (Russia), 58, Translation, Plenum Publishing Corporation, 1126-1132, (1993)
	C320	Mansoor Amiji and Kinam Park, "Surface Modification of Polymeric Materials with Poly (ethylene oxide), Albumin, and Heparin For Reduced Thrombogenicity," Purdue University, School of Pharmacy, West Lafayette, IN 47907

	C321	Manucci, P.M., et al., "Effect of Tamoxifen on Measurements of Hemostasis in Healthy Women", Arch. Intern. Med., 156, 1806-1810, (1996)
	C322	Marx and Marks, "Bench to Bedside: The development of rapamycin and its application to stent restenosis", Circulation 104:852-55 (2001)
	C323	Marx, "CMV-p.53 Interaction May Help Explain Clogged Arteries", Science, 265, 320, (Jul 1994)
	C324	Marzocchi, A., et al., "Restenosis after Coronary Angioplasty: It's Pathogenesis and Prevention," Cardiologia, 36, 309-320 (December, 1991) English Abstract only, reported in Medline, Accession No. 93046311
	C325	Massague and Wotton, "Transcriptional control by the TGF-beta/Smad signaling system", EMBO J., 19(8):1745-54 (2000)
	C326	Massague et al., "Type beta transforming growth factor is an inhibitor of myogenic differentiation", Proc., Natl. Acad. Sci., 83:8206-8210 (1986)
	C327	Massague, "Subunit structure of a high-affinity receptor for type beta-transforming growth factor: evidence for a disulfide-linked glycosylated receptor complex", J. Biol. Chem., 260(11):7059-7066 (1985)
	C328	McAuslan, B.R., et al., "Cellular and Molecular Mechanisms in Angiogenesis", Trans. Ophthal. Soc. U.K., 100, 354-358, (1980)
	C329	McCaffrey et al., "Genomic instability in the type II TGF-b1 receptor gene in atherosclerotic and restenotic vascular cells," J Clin Invest, 100:2182-2188 (1997)
	C330	McCaffrey et al., "Aging and arteriosclerosis: the increased proliferation of arterial smooth muscle cells isolated from old rats is associated with increased platelet-derived growth factor-like activity," J. Exp. Med., 167:163-174 (1988)
	C331	McCaffrey et al., "Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1", J. Clin. Invest., 96:2667-2675 (1995)
	C332	McCaffrey, "TGF-betas and TGF-beta receptors in atherosclerosis," Cytokine and Growth Factor Rev., 11:103-114 (2000)
	C333	McCaffrey, T.A., et al., "Fucoidan is a Non-Anticoagulant Inhibitor of Intimal Hyperplasia", Biochemical and Biophysical Research Communications, 184, 773-781, (1992)
	C334	McCague, R., et al., "An Efficient, Large Scale Synthesis of Idoxifene ((E)-1(4- (2- (N-pyrrolidino) ethoxyl) -1-(4-iodophenyl) -2-phenyl-1-butene)", Organic Preparations and Proc. Int., 26, 343-346, (1994)
	C335	McCague, R., et al., "Synthesis of 4-Stannylated Tamoxifen Analogues: Useful Precursors to Radiolabelled Idoxifene and Axiridinyl 4-Iodotamoxifen.", J. Labelled Compounds and Pharmaceuticals, 34, 297-302, (1994)
	C336	McClean, et al., "cDNA sequence of human apolipoprotein (a) is homologous to plasminogen", Nature, 330, 132-137 (1987), 132-137, (1987)
	C337	McDonald, C.C., et al., "Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial", BMJ, 311, 977-980, (October 14, 1995)
	C338	McDonnell, D.P., et al., "Analysis of Estrogen Receptor Function in Vitro Reveals Three Distinct Classes of Anti estrogens", Molecular Endocrinology, 9, 65-669, (June 1995)
	C339	McLaughlin, C.S., et al., "Inhibition of Protein Synthesis by Trichothecenes", In: Mycotoxins in Human and Animal Health, Pathotox Publishers, Inc., 263-273, (1977)
	C340	McMurray et al., "A standardised method of culturing aortic explants, suitable for the study of factors affecting the phenotypic modulation, migration and proliferation of aortic smooth muscle cells," Atherosclerosis, 86:227-237 (1991)
	C341	Meiser et al., "Effects of Cyclosporin, Fk506, and Rapamycin on Graft-Vessel Disease", The Lancet, 338, 1297-1298 (1991)
	C342	Merck Index, Eleventh Edition 2796, Cytochalasins, p. 438 (1989)
	C343	Merck Index, (Susan Budavari et al, ed.) 1989, p. 1435
	C344	Merrilees and Scott, "Antisense S-oligonucleotide against transforming growth factor-beta 1 inhibits proteoglycan synthesis in arterial wall," L Vase. Res. 31:322-329 (1994)
	C345	Merrilees et al., "Effect of TGF-beta(1) antisense S-oligonucleotide on synthesis and accumulation of matrix proteoglycans in balloon catheter-injured neointima of rabbit carotid arteries, 3". Vasc. Res. 37:50-60 (2000)
	C346	Metcalfe et al., "Calcium and cell proliferation," Br. Med. Bull., 42(4):405-412 (1986)
	C347	Metcalfe, et al., "Protein Markers of Lesion Development in the Vessels of Transgenic Apo(a) Mice" Inflammation, Growth Regulatory Molecules & Atherosclerosis, J. Cellular Biochem., Supplement 18A, p 208, Abstract No. E212 (1994)
	C348	Metcalfe, et al., "Transforming Growth Factor-B and the Protection From Cardiovascular Injury Hypothesis.
	C349	Meyer, S.C., "Functionalized Cytochalasins for Potential Biotechnology Transfer", Ph. D. Thesis (Selected Pages), Syracuse University, New York, 13 p., (May, 1994)
	C350	Michael N. Helmus, "Materials Selection, Chapter 2," Encyclopedic Handbook of Biomaterials and Bioengineering, Part A: Materials, Vol. 1 (1995)
	C351	Michael N. Helmus, "Materials Selection, Chapter 6, Cardiovasc. Pathol. 2(3)(Suppl.):53s-71s (July-Sept. 1993)
	C352	Michael N. Helmus, "Materials Selection for Medical Devices," Spectrum, 1-21, (July 30, 1993)
	C353	Michael N. Helmus, "Medical Device Design--A Systems Approach: Central Venous Catheters", (1990)

	C354	Michael N. Helmus, "Opportunities for Biomaterials," DH Reports, (February 1995)
	C355	Michael N. Helmus, "Technological Advances in Thromboresistant Materials," Spectrum, 1-13 (June 19, 1990)
	C356	Michael N. Helmus, "Thromboresistant Biomaterials: Technical Developments and Applications," Spectrum, (Sept. 12, 1990)
	C357	Middlebrook, J.L., et al., "Binding of T-2 Toxin to Eukaryotic Cell Ribosomes", Biochemical Pharmacology, 38 33110, (1989)
	C358	Milner, M.R., et al., "Usefulness of Fish Oil Supplements in Preventing Clinical Evidence of Restenosis After Percutaneous Transluminal Coronary Angioplasty", Am. J. Cardiol., 64, 294-299 (1989)
	C359	Mintz, G.S., et al., "Chronic Compensatory Arterial Dilation Following Coronary Angioplasty: An Intravascular Ultrasound Study", JACC, Abstract No. 875-97, p. 138A, (Feb., 1994)
	C360	Mintz, G.S., et al., "Geometric Remodeling is the Predominant Mechanism of Clinical Restenosis After Coronary Angioplasty", JACC, Abstract No. 875-42, p. 138A, (Feb., 1994)
	C361	Mintz, G.S., et al., "Mechanisms of Late Arterial Response to Transcatheter Therapy: A Serial Quantitative Angiographic and Intravascular Ultrasound Study", Circulation, 90, Abstract No. 117, p. I-24, (Oct., 1994)
	C362	Mirjalili, N. et al., "Methyl Jasmonate Induced Production of Taxol in Suspension Cultures of Taxus Cuspidata: Ethylene Interaction and Induction Models", Biotechnol. Prog., 12, 110-118, (1996)
	C363	Mirjalili, N., et al., "Gas Phase Composition Effects on Suspension Cultures of Taxus cuspidata", Biotechnology and Bioengineering, 48, 123-132, (1995)
	C364	Mitchell, L.L., et al., "Copper Deficiency Depresses Rat Aortae Superoxide Dismutase Activity and Prostacyclin Synthesis", Prostaglandins, 35, 977-986, (1988)
	C365	Molling, K., "Naked DNA for Vaccine or Therapy", J. Mol. Med., 75, 242-246, (1997)
	C366	Moorthy, B., et al., "Tamoxifen Metabolic Activation: Comparison of DNA Adducts Formed by Microsomal and Chemical Activation of Tamoxifen and 4-Hydroxytamoxifen with DNA Adducts Formed in Vivo", Cancer Research, 56, 53-57, (Jan. 1, 1996)
	C367	More, R.S., et al., "A targeted antithrombotic conjugate with antiplatelet and fibrinolytic properties which reduces in vivo thrombus formation", Chemical Abstracts, Vol. 120, No. 22, (May 30, 1994)
	C368	Morris et al., "Rapamycin (sirolimus) inhibits vascular smooth muscle DNA synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and nonimmune cells," Transplant Proc, 27:430-31 (1995)
	C369	Morris, R.E., "Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides", Transplantation Reviews, 6, 39-87, (1992)
	C370	Morris, R.E., et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", Transplantation Proceedings, 23, 19-25, (1991)
	C371	Mosedale and Grainger, "An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system," Biochem J., 343:125-133 (1999)
	C372	Mosedale, D.E. University of Cambridge Ph.D. Thesis, Differentiated state of smooth muscle and its relationship to TGF- β in vivo, DJG 005652-005910 (1998) and all references therein
	C373	Mosedale, D.E., et al., "Transforming Growth Factor-beta is Correlated with Smooth Muscle Cell Differentiation in Vivo", Circulation, 90, 67 th Scientific Session, Abstract No. 1590, p. I-296, (Oct., 1994)
	C374	Mueller, B.M., et al., "Antibody Conjugates with Morpholinodoxorubicin and Acid-Cleavable Linkers", Bioconjugate Chem. 1, 325-330, (1990)
	C375	Murphy, C.S., et al., "Structural Components Necessary For The Antiestrogenic Activity of Tamoxifen", J. Steroid Biochem, 34, 1-6 (1989)
	C376	Murphy, C.S., et al., "Structure-Activity Relationships of Nonisomerizable Derivatives of Tamoxifen: Importance of Hydroxyl Group and Side Chain Positioning for Biological Activity", Molecular Pharmacology, 39, 421-428, (1991)
	C377	Murphy, L.C., et al., "Differential Effects of Tamoxifen and Analogs with Nonbasic Side Chains on Cell Proliferation in Vitro", Endocrinology, 116, 1071-1078, (1985)
	C378	Myer, R.O, et al., "Performance and Carcass Characteristics of Swine When Fed Diets Containing Canola Oil and Added Copper to Alter the Unsaturated:Saturated Ratio of Pork Fat", J. Anim. Sci., 70, 1417-1423, (1992)
	C379	Nabel, E.G., et al., "Direct Transfer of Transforming Growth Factor Beta 1 Group Into Arteries Stimulates Fibrocellular Hyperplasia", Proc. Natl. Acad. Sci. USA, 90, 10759-10763, (1993)
	C380	Nagakawa, Y., et al., "Effect of Eicosapentaenoic Acid on the Platelet Aggregation and Composition of Fatty Acid in Man", Atherosclerosis, 47, 71-75, (1983)
	C381	Nakagawa, et al., "A Case of Acute Myocardial Infarction Intracoronary Arteries Due To Hormone Therapy.", Angiology, 45, 333-338, (May 1994)
	C382	Nakano, "Glucocorticoid Inhibits Thrombin-Induced Expression of Platelet-Derived Growth Factor A-chain and Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells:, The Journal of Biological Chemistry, 268, 22941-22947 (1993)
	C383	Navarro, S.E., et al., "Notes from Transcatheter Cardiovascular Therapeutics 1995 Conference", USB Securities, Equity Research -- Medical Technology, 10 p., (Mar. 3, 1995)
	C384	Nayfield, S.G., et al., "Tamoxifen-Associated Eye Disease: A Review", Journal of Clinical Oncology, 14(3), 1018-1026, (1996)
	C385	Nikol et al., "Persistently increased expression of the transforming growth-factor-131 gene in human vascular

		restenosis: Analysis of 62 patients with one or more episode of restenosis," Cardiovasc. Pathol., 3:57-64 (1994)
	C386	O'Leary, V.J., et al., "The Resistance of Low Density Lipoprotein to Oxidation Promoted by Copper and Its Used as an Index of Antioxidant Therapy", Atherosclerosis, 119, 169-179, (1996)
	C387	Ohno, et al., "Gene Therapy for Vascular Smooth Muscle Proliferation After Arterial Injury", Science, 265, 781-784, (August 5, 1994)
	C388	Okuyama, S., et al., "Copper Complexes of Non-Steroidal Anti-inflammatory Agents: Analgesic Activity and Possible Opioid Receptor Activation", Agents and Actions, 21, 130-144, (1987)
	C389	Opherk, D., et al., "Four-Year Follow-up Study in Patients With Angina Pectoris and Normal Coronary Arteriograms ("Syndrome X")", Circulation, 80, 1610-1616, (1989)
	C390	Orlov, S.N., et al., "Altered beta-Adrenergic Regulation of Na-K-Cl Cotransport in Cultured Smooth Muscle Cells Form the Aorta of Spontaneously Hypertensive Rats", American Journal of Hypertension, 8, 739-747, (1995)
	C391	Osborne, M.R., et al., "Identification of the Major Tamoxifen-Deoxyguanosine Adduct Formed in the Liver DNA of Rats Treated with Tamoxifen", Cancer Research, 56, 66-71, (1996)
	C392	Owens, G.K., et al., "Transforming Growth Factor-B-induced Growth Inhibition and Cellular Hypertrophy in Cultured Vascular Smooth Muscle Cells", The Journal of Cell Biology, 107, 771-780, (1988)
	C393	Ozer, et al., "New Roles of low density lipoproteins and vitamin E in the pathogenesis of atherosclerosis", Biochem Mol. Biol. Intern, 35, 117-124, (1995)
	C394	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents in Dogs with Chronic Portal Hypertension," A JR 1986 Dee; 147:1251-54.
	C395	Palmaz et al., "Expandable Intrahepatic Portacaval Shunt Stents: Early Experience in the Dog," 145 Am. J. Roentgenol. 1985;145:821-825.
	C396	Palmaz et al., "Expandable Intraluminal Grafting in Atherosclerotic Rabbit Aortas," Radiology 1985 Nov; 157(P):66 Abs 130.
	C397	Palmaz et al., "Normal and Stenotic Renal Arteries: Experimental Balloon-expandable Intraluminal Stenting," Radiology 1987 Sept; 164(3):705-708.
	C398	Palmaz et al., "Removable Biliary Endoprosthesis," Am, J. Roentgenol. 1983;140(4):812-4.
	C399	Palmaz, et al., "Atherosclerotic Rabbit Aortas: Expandable Intraluminal Grafting," Radiology 1986 Sept; 160:723-726.
	C400	Palmaz, et al., "Expandable Intrahepatic Portocaval Shunt Stents in Dogs with Chronic Portal Hypertension," American Roentgen Ray Soc'y 1986 Annual Meeting, Washington, D.C., (BT 000079) (April 13-18, 1986).
	C401	Palmaz, et al., "Intravascular Stents: Basic Physical and Biological Properties, Endoluminal Treatment: The Different Techniques." Editors Michel Henry, Max Arnor, Edward B. Diethrich and Barry Katzen. Published by Springer Verlag; 4:149-158 (1997).
	C402	Palmaz, J.C. "Balloon-Expandable Intravascular Stent," A JR 1988 June; 150:1263-1269.
	C403	Palmaz, J.C. "Expandable Intraluminal Graft: A Preliminary Study," Radiology 1984 Nov;153(P):329 Abs. 993.
	C404	Pandey, B.L., et al., "A Study of the Effects of Tamrabhasma, an Indigenous Preparation of Copper on Experimental Gastric Ulcers and Secretion", Indian Journal of Experimental Biology, 21, 258-264, (1983)
	C405	Pardoll, D., et al., "Exposing the Immunology of Naked DNA Vaccines", Immunity, 3, 165-169, (1995)
	C406	Parthasathiy, S., et al., "A Role for Endothelial Cell Lipoxigenase in the Oxidative Modification of Low Density Lipoprotein", Proc. Nat'l Acad. Sci., USA, 86, 1046-1050, (1989)
	C407	Pedron, N. et al., "The Effect of Acetylsalicylic Acid on Menstrual Blood Loss in Women with IUDs", Contraception, 36, 295-303, (1987)
	C408	Peng et al., "The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation," Mol. Cell. Biol., 22:5575-84 (2002)
	C409	Pennisi, E., "Drug's Link to Genes Reveals Estrogen's Many Sides", Science, 273, 1171, (Aug. 30, 1996)
	C410	Peress, N.S., et al., "Differential Expression of TGF-B1, 2 and 3 Isotypes in Alzheimer's Disease : A Comparative Immunohistochemical Study with Cerebral Infarction, Aged Human and Mouse Control Brains", Journal of Neuropathology and Experimental Neurology, 54, 802-811, (November 1995)
	C411	Peress, N.S., et al., "Glial Transforming Growth Factor (TGF) -B Isotypes in Multiple Sclerosis: Differential Glial Expression of TGF- B1, 2, and 3 Isotypes in Multiple Sclerosis", Journal of Neuroimmunology, 71, 115-123, (1996)
	C412	Perez, J.R., et al., "Regulation of Adhesion and Growth of Fibrosarcoma Cells by NF - kb RelA Involves Transforming Growth Factor Beta", Molecular and Cellular Biology, 14, 5326-5332, (1994)
	C413	Pfister, W.R. et al., "Silicone Based Sustained and Controlled Release Drug Delivery Systems", 1985, 30 th National SAMPE Symposium and Exhibition, Anaheim, CA, March 19-21, 1985, pp. 490-498 (1985)
	C414	Pinto, H.C., et al., "Tamoxifen-associated Steatohepatitis C Report of Three Cases", Journal of Hepatology, 23, 95-97, (1995)
	C415	Polysciences Inc., TDMAC-Heparin Coatings, Nov. 1988, Data Sheet #172
	C416	Post et al., "The Relative Importance of Arterial Remodeling Compared With Intimal Hyperplasia in Lumen Renarrowing After Balloon Angioplasty" Circulation 89, 2816-2821 (June 1994)
	C417	Potter et al., "A mechanism hypothesis for DNA adduct formation following hepatic oxidative metabolism," Carcinogenesis, 15, 439-442 (1994)

	C418	Powell et al., "Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury," Science, 245:186-188 (1989)
	C419	Presentation at The Society of CV & Interventional Radiology's Twelfth Annual Course On "Diagnostic Angiography and Interventional Radiology." Includes: "The Current Status of Vascular Prostheses" by Julio Palmaz at 118-120 (March 23 - 26 1987).
	C420	Program and abstracts of the Seventh International Conference on the Adjuvant Therapy of Cancer, held in Tuscon, Arizona on March 10-13, 1993
	C421	Pupita, G., et al., "Myocardial Ischemia Caused by Distal Coronary-Artery Constriction in Stable Angina Pectoris", The New England Journal of Medicine, 323, 514-520, (1990)
	C422	Rainsford, K.D., et al., "Concerning the Merits of Copper Aspirin as a Potential Anti-Inflammatory Drug", J. Pharm. Pharmac., 28, 83-86, (1976)
	C423	Rainsford, K.D., et al., "Gastric Mucus Effusion Elicited by Oral Copper Compounds: Potential Anti-Ulcer Activity", Experientia, 32, 1172-1173, (1976)
	C424	Raisz, L.G., "Estrogen and Bone: New Pieces to the Puzzle", Nature Medicine, 2, 1077-1078, (1996)
	C425	Raloff, "Tamoxifen Puts Cancer on Starvation Diet", Science News, 146, 292, (November 5, 1994)
	C426	Ray, P., et al., "Repression of interleukin-6 gene expression by 17beta-estradiol: Inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-6B by the estrogen receptor", FEBS Letters, 409, 79-85, (1997)
	C427	Razavi, M., "Unusual Forms of Coronary Artery Disease", Cleveland Clinic Consultations, 7, 25-46, (1975)
	C428	Recchia, F., et al., "Interferon-beta, Retinoids, and Tamoxifen in the Treatment of Metastatic Breast Cancer: A Phase II Study", Journal of Interferon and Cytokine Research, 15, 605-610, (1995)
	C429	Reckless, J., et al., "Tamoxifen Decreases Cholesterol Sevenfold and Abolishes Lipid Lesion Development in Apolipoprotein E Knockout Mice", Circulation, 95, 1542-1548, (1997)
	C430	Reilly et al., "Antiproliferative effects of heparin on vascular smooth muscle cells are reversed by epidermal growth factor," J. Cell Physiol., 131 :t 49-157 (1987)
	C431	Reilly, C.F., "Rat Vascular Smooth Muscle Cells Immortalized with SV40 Large T Antigen Possess Defined Smooth Muscle Cell Characteristics Including Growth Inhibition by Heparin", Journal of Cellular Physiology, 142, 342-351, (1990)
	C432	Reis, G.J., et al., "Randomized Trial of Fish Oil for Prevention of Restenosis After Coronary Angioplasty", The Lancet, 177-181, (1989)
	C433	Ribeiro, G., et al., "Adjuvant Tamoxifen for Male Breast Cancer (MBC)", Br. J. Cancer, 65, 252-254, (1992)
	C434	Rieckmann, P., et al., "Tumor Necrosis Factor-a Messenger RNA Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Associated with Disease Activity", Ann. Neurol, 27, 82-88, (1996)
	C435	Riessen et al., "Prospects for Site-Specific Delivery of Pharmacologic and Molecular Therapies", J. Amer. Collage of Cardiol., 23 , 1234-1244 (Apr. 1994)
	C436	Riessen et al., "Regional Differences in the Distribution of the Proteoglycans Biglycan and Decorin in the Extracellular Matrix of Atherosclerotic and Restenotic Human Coronary Arteries", Amer. J. Path 144, 962-974 (May 1994)
	C437	Roberts et al., "Type beta transforming growth factor: a bifunctional regulator of cellular growth," Proc. Natl. Acad. Sci., 82:119-123 (1985)
	C438	Robinson, J.R. (ed), "Sustained and Controlled Release Drug Delivery Systems," New York, Marcel Dekker (1978). Chapters 1-2, 4, and 7-9.
	C439	Roche Lexikon Medizin, Urban und Schwarzenberg, 1984, page 69 "Antibiotika", and page 515 "Fibrin"
	C440	Rompp Chemie-Lexikon, 9 th ed., pages 206-208, pages 1350 and 1351
	C441	Rompp, Chemie-Lexikon, 8 th ed., 1987, page 2633 "Mitosehemmer"
	C442	Roubin, "Intracoronary Stenting of Canine Coronary Arteries After Percutaneous Coronary Angioplasty (PTCA)," Circulation 1986 Oct;74(Supp. II-458):1825 Abstract.
	C443	Rowinsky et al., "Taxol: Twenty years Later, the Story Unfolds," Journal of the National Cancer Institute, 1991, Vol 83 No. 24 pp 1778-1781
	C444	Rutqvist, L.E., et al., "Cardiac and Thromboembolic Morbidity Among Postmenopausal Women with Early-Stage Breast Cancer in a Randomized Trial of Adjuvant Tamoxifen", Journal of the National Cancer Institute, 85, 1398-1406, (1993)
	C445	Rutsch, et al., "Benestent-II Pilot Study: 6 months Follow Up of Phase I" Abstract, Society of Cardiology, (1995)
	C446	Ruygrok and Serruys, "From Bench to Bedside, Intracoronary Stenting, From Concept to Custom," Circulation 1996; 94:882-890
	C447	Ryan et al., "Transforming growth factor-beta-dependent events in vascular remodeling following arterial injury," J.. Vase. Res., 40:37-46 (2003)
	C448	Saarto, T., et al., "Antiatherogenic Effects of Adjuvant Antiestrogens: A Randomized Trial Comparing the Effects of Tamoxifen and Toremifene on Plasma Lipid Levels in Postmenopausal Women with Node-Positive Breast Cancer", Journal of Clinical Oncology, 14, 429-433, (February 1996)
	C449	Sabatini et al., "RAFT1: a mammalian protein that binds to FK.BP12 in a rapamycin-dependent fashion and is homologous to yeast TORs", Cell, 78:35-43 (1994)

	C450	Saito, H., et al., "Influence of Maternal Drug Metabolism on the Fetal Toxicity Induced by Acetylsalicylic Acid", <i>The Journal of Toxicological Sciences</i> , 7, 177-184, (1982)
	C451	Sanchez, et al., "Control of Contact activation on end-point immobilized heparin, The role of antithrombin and the specific antithrombin-binding sequence," <i>J. Of Biomedical Materials Research</i> , pp. 655-661 (1995)
	C452	Sanderson et al., "Antibody-Coated Microspheres for Drug Delivery to Prevent Restenosis", <i>Circulation</i> , 90, I 508, Abstract No. 2734 (October 1994)
	C453	Sargent, L.M., et al., "Induction of Hepatic Aneuploidy in Vivo by Tamoxifen, Toremifene and Idoxifene in Female Sprague-Dawley Rats", <i>Carcinogenesis</i> , 17, 1051-1056, (1996)
	C454	Schatz et al., "Balloon Expandable Intravascular Stents in Diseased Human Cadaver Coronary Arteries," <i>Circulation</i> 1987 Oct;70(4): Abstract 0102.
	C455	Schatz et al., "Balloon-expandable Intra-coronary Stents In The Adult Dog," <i>Circulation</i> 1987 Aug; 76(2):450-457.
	C456	Schatz, et al., "Balloon Expandable Intracoronary Stents In Dogs," <i>Circulation</i> 1986 Oct;74(Supp. II-458): 1824 Abstract,
	C457	Schatz, et al., "Clinical Experience with the Palmaz-Schatz Stent: Initial Results of A Multicenter Study," <i>Circulation</i> 1991 Jan;83(1): 148-161.
	C458	Schatz, R.A. Introduction to Intravascular Stents, <i>Cardiology Clinics</i> 1988 Aug;6(3):357-72.
	C459	Schlaak, J.F., et al., "Different Cytokine Profiles in the Synovial Fluid of Patients with Osteoarthritis, Rheumatoid Arthritis and Seronegative Spondylarthropathies", <i>Clinical and Experimental Rheumatology</i> , 14, 155-162, (1996)
	C460	Schmidt, E.B., et al., "Long-Term Supplementation with n-3 Fatty Acids, II: Effect on Neutrophil and Monocyte Chemotaxis", <i>Scand. J. Clin. Lab. Invest.</i> , 52, 229-236, (1992)
	C461	Schoenemanne, et al., "The Differential Diagnoses of Spontaneous Pneumothrax and Pulmonary Lymphangioleiomyomatosis Clinical Picture Diagnoses and Theory.", <i>Chiracq</i> , 61, 301-303 (1990); reported in <i>Biosis</i> , 90, 432367 (1990), English abstract only
	C462	Schulick et al., "Overexpression of transforming growth factor beta1 in arterial endothelium causes hyperplasia, apoptosis, and cartilaginous metaplasia," <i>PNAS</i> 95:6983-6988 (1998)
	C463	Schwartz, C.J., et al., "The Pathogenesis of Atherosclerosis: An Overview", <i>Clin. Cardiol.</i> , 14, I-1--I-16, (1991)
	C464	Schwartz, G.G., et al., "Pathophysiology of Chronic Stable Angina", In: <i>Atherosclerosis and Coronary Artery Disease</i> , V. Fuster, et al., (eds.), Lippencott-Raven Publishers, Philadelphia, pp. 1386-1400, (1996)
	C465	Sedlacek, S. "Estrogenic Properties of Tamoxifen on Serum Lipids in Postmenopausal Women with Breast Cancer (BCA)", <i>Breast Cancer Research and Treatment</i> , 14, Abstract No. 82, 153, (1989)
	C466	Sehgal et al., "Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization." <i>J. Antibiot.</i> , 28:727-32 (1975)
	C467	Sehgal, "Sirolimus: its discovery, biological properties, and mechanism of action." <i>Transplant. Proc.</i> , 35(3 Suppl):7S-148 (2003)
	C468	Serruys et al., "The new angiotensin converting enzyme inhibitor cilazapril does not prevent restenosis after coronary angioplasty: the results of the MERCATOR trial," <i>JACC</i> 19:258A, Abstract 783-2 (1992)
	C469	Serruys, et al., "A Comparison of Balloon-Expendable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", <i>The New England Journal of Medicine</i> , 331, 489-495 (August, 1994)
	C470	Serruys, P.W., et al., "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries -- Early Outcome of the Benestent-II Pilot Study", <i>Circulation</i> , 93, 412-422, (Feb. 1996)
	C471	Shanahan and Weissberg, "Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo," <i>Arterioscler. Thromb. Vase. Biol.</i> , 18(2):333-338 (1998)
	C472	Shanahan, C.M., et al., "High Expression of Genes for Calcification-regulating Proteins in Human Atherosclerotic Plaques", <i>Journal of Clinical Investigation</i> , 93, 2393-2402, (June, 1994)
	C473	Shapiro, L.M., "Echocardiographic Features of Impaired Ventricular Function in Diabetes Mellitus", <i>British Heart Journal</i> , 47, 439-444, (1982)
	C474	Shemon, et al., "Tamoxifen Decreases Lipoprotein(a) in Patients with Breast Cancer.", <i>Metabolism</i> , 43, 531-532, (May 1994)
	C475	Shewmon, et al., "Tamoxifen and Estrogen Lower Circulating Lipoprotein(a) Concentration in Healthy Postmenopausal Women", <i>Arteriosclerosis and Thrombosis</i> , 14, 1589-1593, (1994)
	C476	Shimaoka, I., et al., "Purification of a Copper Binding Peptide from the Mushroom <i>Grifola Frondosa</i> and Its Effect on Copper Absorption", <i>J. Nutr. Biochem.</i> , 4, 33-38, (1993)
	C477	Shou et al., "Cardiac defects and altered ryanodine receptor function in mice lacking FK-BP 12," <i>Nature</i> , 391 (6666):489-92 (1998)
	C478	Siebenlist, U., et al., "Structure, Regulation and Function of NF-kB", <i>Annu. Rev. Cell. Biol.</i> , 10, 405-455, (1994)
	C479	Sigwart, et al., "Intravascular Stents to Prevent Occlusion and Restenosis After Transluminal Angioplasty," <i>N. Engl. J. Med.</i> , Mar. 19, 1987, Vol. 316, No. 12, pp.701-06
	C480	Sigwart, U., Frank, G.I., "Bioabsorbable, Drug-Eluting, Intracoronary Stents: Design and Future Applications," <i>Coroinary Stents</i> . Springer-Verlag (1992)
	C481	Sigwart, Ulrich, "The Self Expanding Mesh Stent" <i>Textbook of Interventional Cardiology</i> , (Eric J. Topol, ed) 1990, Chapter 29, pp 605-622
	C482	Silber, S. "Drug-eluting stents: aktueller Stand", internet article on http://sigmund-silber.com/deutsch/varia/var-

		2003/03-09-5-Silber-Chemnitz.pdf of August 6, 2003
	C483	Sismondi, et al., "Metabolic Effects of Tamoxifen in Postmenopause.", <i>Anticancer Res.</i> , 14, 2237-2244, (1994)
	C484	Soderberg, L.S., et al., "Copper (II) (3,5-Diisopropylsalicylate) sub2 Accelerates Recovery of B and T Cell Reactivity Following Irradiation", <i>Scand J. Immunol.</i> , 26, 495-502, (1987)
	C485	Soderberg, L.S., et al., "Copper (II) sub2(3, 5-diisopropylsalicylate) sub4 Stimulates Hemopoiesis in Normal and Irradiated Mice", <i>Exp. Hematol.</i> , 18, 577-580, (1988)
	C486	Soderberg, L.S., et al., "Postirradiation Treatment with Copper (II) sub2 (3,5-diisopropylsalicylate) sub4 Enhances Radiation Recovery and Hemopoietic Regeneration", <i>Exp. Hematol.</i> , 18, 801-805, (1990)
	C487	Soderberg, L.S., et al., "Radiation Recovery Agents", <i>DN & P</i> , 3, 600-605, (1990)
	C488	Sollott, S.J., et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", <i>The Journal of Clinical Investigation</i> , 95, 1869-1876, (Apr., 1995)
	C489	Song "Dexamethasone-nanoparticles for intra-arterial localization in restenosis in rats," <i>Proceed. Intern. Symp. Control. Rel. Mater.</i> , 22, 444-445 (1995)
	C490	Song, J., et al., "Tamoxifen (Estrogen Antagonist) Inhibits Voltage-Gated Calcium Current and Contractility in Vascular Smooth Muscle from Rats", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 227, 1444-1453, (1996)
	C491	Sorenson, J.R., "Copper Complexes Offer a Physiological Approach to Treatment of Chronic Disease", <i>Progress in Medicinal Chemistry</i> , 26, 437-568, (1989)
	C492	Sorenson, J.R., "Essential Metalloelement Metabolism and Radiation Protection and Recovery", <i>Radiation Research</i> , 132, 19-29, (1992)
	C493	Sorenson, J.R., "Pharmacological Activities of Copper Compounds", In: <i>Handbook of Metal-Ligand Interactions in Biological Fluids -- Bioinorganic Medicine</i> , vol. 2, Berton, G., (ed.), Marcel Dekker, Inc., New York, 1128-1139, (1995)
	C494	Sorenson, J.R., "Radiation Protection and Radiation Recovery with Essential Metalloelement Chelate", <i>P.S.E.B.M.</i> , 210, 191-204, (1995)
	C495	Sorenson, J.R., "The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real", <i>Journal of Pharmaceutical Sciences</i> , 73, Open Forum, 1875-1878, (1984)
	C496	Sorenson, J.R., et al., "Antieoplastic Activities of Some Copper Salicylates", In: <i>Trace Substances in Environmental Health</i> , vol. XVI, Hemphill, D.D., (ed.), University of Missouri, Columbia, 362-369, (1982)
	C497	Sorenson, J.R., et al., "Bis (3, 5-diisopropylsalicylate) copper (II), a Potent Radioprotectant with Superoxide Dismutase Mimetic Activity", <i>J. Med. Chem.</i> , 27, 1747-1749, (1984)
	C498	Sorenson, J.R., et al., "Copper Complexes as 'Radiation Recovery' Agents", <i>Chemistry in Britain</i> , 25, 169-171, (1989)
	C499	Sorenson, J.R., et al., "Copper-, Iron-, Manganese- and zinc-3, 5-diisopropylsalicylate Complexes Increase Survival of Gamma-Irradiated Mice", <i>Eur. J. Med. Chem.</i> , 28, 221-229, (1993)
	C500	Sousa et al., "Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up," <i>Circulation</i> , 104:2007-i 1 (2001) (CYP228071-228075)
	C501	Sousa et al., "Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries," <i>Circulation</i> . 107(3):381-3 (2003) (BSX 024170-024172)
	C502	Sousa, J.E. et al., "New Frontiers in Cardiology Drug-Eluting Stents: Part I", <i>Circulation</i> , 2003, 107:2274-2279,
	C503	Southgate and Newby, "Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP," <i>Atherosclerosis</i> , 82:113-123 (1990)
	C504	Srivastava, K.C., "Effects of Dietary Fatty Acids, Prostaglandins and Related Compounds on the Role of Platelets in Thrombosis", <i>Biochem. Exp. Biol.</i> , 16, 317-338, (1980)
	C505	Standley, P.R., et al., "Tamoxifen (an Antiestrogen) Reduces K Positive- and Agonist-Induced Vascular Contractility in Rat Resistance Vessels", Abstract No. 159 (Source and Date Unavailable)
	C506	Stevenson, F., et al., "Idiotypic DNA Vaccines against B-cell Lymphoma", <i>Immunological Reviews</i> , 145, 221-228, (1995)
	C507	Stork, G., et al., "Total Synthesis of Cytochalasin B", <i>Journal of the American Chemical Society</i> , 100, 7775-7777, (1978)
	C508	Stouffer, et al., "TGF beta Has a Biphasic, Concentration Dependant Effect on EFG and PDGR-BB Induced Smooth Muscle Cell Proliferation, Inflammation, Growth Regulatory Molecules and Atherosclerosis.", <i>J. Cellular Biochem, Supplement 18A</i> , Abstract No. A321, 288, (1994)
	C509	Streptetti, A.V., et al., "Formation of Myointimal Hyperplasia and Cytokine Production in Experimental Vein Grafts", <i>Surgery</i> , 123(4), 461-469, (1998)
	C510	Suckling, "Atherosclerosis Patents: Clues to the Next Drug Generation", <i>Bio/Tech</i> , 12 1379-1380 (December 1994)
	C511	Sudo, K., et al., "Antiestrogen-Binding Sites Distinct from the Estrogen Receptor: Subcellular Localization, Ligand Specificity, and Distribution in Tissues of the Rat", <i>Endocrinology</i> , 112, 425-434, (1983)
	C512	Swain, "Blazing new paths for product introductions," <i>Medical Device & Diagnostic Industry</i> , Sept. 2003, p. 68-81
	C513	Szekanecz, Z., et al., "Increased Synovial Expression of Transforming Growth Factor (TGF) -B Receptor Endoglin and TGF- B1 in Rheumatoid Arthritis: Possible Interaction in the Pathogenesis of the Disease", <i>Clinical Immunology and Immunopathology</i> , 76, 187-194, (August 1995)

	C514	Tabas et al., "the Actin Cytoskeleton in Important for the Stimulation of Cholesterol Esterification by Atherogenic Lipoproteins in Macrophages" J. Biol. Chem., 269, 22547-22556 (Sept. 9 1994)
	C515	Takashima, K. et al., "The Hypocholesterolemic Action of TA-7552 and its Effects on Cholesterol Metabolism in the Rat", Atherosclerosis, 107, 247-257, (1994)
	C516	Tanaka et al., "Ialpa 25 (OH) 303 Exerts Cytostatic effects on Murine Osteosarcoma Cells and Enhance Cytocidal Effects on Anticancer Drugs" Clinical Orthopaedics and related Research no. 247 1989 pgs. 290-296
	C517	Tanaka et al., "Prominent Inhibitory Effects of Tranilast on Migration and Proliferation of and Collagen Synthesis by Vascular Smooth Muscle Cells" Atherosclerosis, 107, 179-185 (1994)
	C518	Tanenbaum, S.W., "Microbiological, Preparative and Analytical Aspects of Cytochalasin Production", In: Cytochalasins -- Biochemical and Cell Biological Aspects, Tanenbaum, S.W., (ed.), Elsevier/North-Holland Biomedical Press, 2-14, (1978)
	C519	Tang et al., "Regression of collagen-induced arthritis with taxol, a microtubule stabilizer". Arthritis and Rheumatism, 36 (9) Suppl.:S45, 1993
	* C520	Tawashi, R., "The dissolution rates of crystalline drugs" , J. Mond. Pharm, 4,11,1968, pp 371-379
	C521	Teirstein (ed.), "Coronary Stents: pros and cons," Coronary Artery Disease, 5:561-600 (1994).
	C522	Tessari et al., "Antiproliferative activity of unfractionated heparin on a human smooth muscle cell line, Pharmacol." Res., 21:145-6 (1989)
	C523	Testart, J., et al., "The Action of Anti-Inflammatory Drugs to the Fertility of Female Rats with Intrauterine Contraceptive Devices", J. Reprod. Fert., 63, 257-261, (1981)
	C524	Thompson, J.T., et al., "Comparison of Recombinant Transforming Growth Factor-beta -2 and Placebo as an adjunctive Agent for Macular Hole Surgery", Ophthalmology, 15(4), 700-706, (1998)
	C525	Thompson, N.L., et al., "Expression of Transforming Growth Factor-B1 in Specific Cells and Tissue of Adult and Neonatal Mice", Journal of Cell Biology, 108, 661-669, (1989)
	C526	Tong et al., "Non-Thrombogenic Hemofiltration System for Acute renal failure Treatment: ASAIO Trans. 38: M702-M706 (1992)
	C527	Toomasian et al., "Evaluation of Duraflon II Heparin Coating in Prolonged Extracorporeal Membrane Oxygenation", ASAIO Trans 34: 410-14 (1988)
	C528	Topol, E. et al., "Frontiers in Interventional Cardiology" Circulation, 1998, 98:1802-1820,
	C529	Treasure, C.B., et al., "Hypertension and Left Ventricular Hypertrophy Are Associated With Impaired Endothelium-Mediated Relaxation in Human Coronary Resistance Vessels", Circulation, 87, 86-93, (1993)
	C530	Treiber, A., et al., "Chemical and Biological Oxidation of Thiophene: Preparation and Complete Characterization of Thiophene S-Oxide Dimers and Evidence for Thiophene S-Oxide as an Intermediate in Thiophene Metabolism in vivo and In Vitro", J. Am. Chem. Soc., 119, 1565-1571, (1997)
	C531	Tucker et al., "Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor," Science, 226:705-707 (1984)
	C532	Ulman, et al., "Drug Permeability of Modified Silicone Polymers," Journal of Controlled Release 1989; 10:276-281
	C533	Ulman, K.L. et al., "Drug Permeability of Modified Silicone Polymers", J. Controlled Release, 10:251-260 (1989)
	C534	Van Der Giessen, <i>et al.</i> , "Coronary Stenting With Polymer-Coated And Uncoated Self-Expanding Endoprosthesis In Pigs" Coron. Art. Disease 1992; 3:631-40
	C535	Van Der Giessen, <i>et al.</i> , "Self-expandable Mesh Stents: an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs" "Circulation 82:III-542 (1990)
	C536	Van Sickle, W.A., et al., "An Alternative Mechanism for the Inhibition of Cholesterol Biosynthesis in HepG2 Cells by N- [(1,5,9) -Trimethyldecyl] -4alpha, 10-dimethyl 8-aza-trans-decal-3beta-ol (MDL 28, 815)", The Journal of Pharmacology and Experimental Therapeutics, 267, 243-1249, (1993)
	C537	Vawter, M.P., et al., "TGF B1 and TGF B2 Concentrations are Elevated in Parkinson's Disease in Ventricular Cerebrospinal Fluid", Experimental Neurology, 141, 313-332, (1996)
	C538	Vidensek N., et al., "Taxol Content in Bark, Wood, Root, Leaf, Twig, and Seedling from Several Taxus Species", Journal of Natural Products, 53, 1609-1610, (Nov./Dec., 1990)
	* C539	Voigt, R., Lehbuch der pharmazeutischen Technologie, 5 th . edition VEB Verlag Volk und Gesundheit Berlin, 1984, p 689
	C540	Von Schacky, C., et al., "Long-Term Effects of Dietary Marine omega-3 Fatty Acids upon Plasma and Cellular Lipids, Platelet Function, and Eicosanoid Formation in Humans", J. Clin. Invest., 76, 1626-1631, (1985)
	C541	Waksman, R., et al., "Intracoronary Radiation Before Stent Implantation Inhibits Neointima Formation in Stented Porcine Coronary Arteries", Circulation, 92, 1383-1386, (1995)
	C542	Wallace, et al., "Tracheobronchial Tree: Expandable Metallic Stents Used in Experimental and Clinical Applications," RADIOLOGY 1986 Feb;158(2):309-12.
	C543	Wallace, J.M., et al., "Dietary Fish Oil Supplementation Alter Leukocyte Function and Cytokine Production in Healthy Women", Arteriosclerosis, Thrombosis and Vascular Biology, 15, 185-189, (1995)
	C544	Waller et al., "Crackers, Breakers, Stretchers, Drillers, Scrappers, Shavers, Burners, Welders and Melters: The Future Treatment of Atherosclerotic Coronary Artery Disease?" A Clinical-Morphologic Assessment," JACC

		13:969-87 (1989)
	C545	Waller et al., "Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia," <i>Transpl. Int.</i> 17:9-14 (2004)
	C546	Waller et al., "Mycophenolate mofetil inhibits intimal hyperplasia and attenuates the expression of genes favouring smooth muscle cell proliferation and migration," <i>Transplant Proc.</i> 37(1): 164-6 (2005).
	C547	Waller, B.F. X.L., et al., "Atherosclerotic and Nonatherosclerotic Coronary Artery Factors in Acute Myocardial Infarction", In: <i>Acute Myocardial Infarction</i> , Pepine, C.J., (ed.), F.A. Davis Company, Philadelphia, 29-104, (1989)
	C548	Waltermberger, "Modulation of growth factor action: implications for the treatment of cardiovascular diseases," <i>Circulation</i> , 96:4083-4094 (1997)
	C549	Wang, X.L., et al., "Circulating Transforming Growth Factor Betal and Coronary Artery Disease", <i>Cardiovascular Research</i> , 34, 404-410, (1997)
	C550	Ward et al., "Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries," <i>Atherosclerosis</i> , 137:267-
	C551	Ward et al., "Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting," <i>Arterioscler. Thromb. Vasc. Biol.</i> 22:940-948 (2002);
	C552	Watson, et al., "TGF-B1 and 25-Hydroxcholesterol Stimulate Osteoblast-Like Vascular Cells to Calcify", <i>J. Clin. Invest.</i> , 93, 2106-2113, (May 1994)
	C553	Wei, C.M. et al., "Binding of Trichodermin to Mammalian Ribosomes and Its Inhibition by Other 12, 13-Epoxytrichothecenes", <i>Molecular & Cellular Biochemistry</i> , 3, 215-219, (May 30, 1974)
	C554	Weissberg, P.L., et al., "Is Vascular Smooth Muscle Cell Proliferation Beneficial?", <i>Lancet</i> , 347, 305-307, (Feb. 3 1996)
	C555	West, G.B., "Comments on 'The Ulcerogenic Potential of Copper Aspirinate Seems to be More Imaginary than Real'", <i>Journal of Pharmaceutical Sciences</i> , 74; Open Forum, 700, (1985)
	C556	West, G.B., "Testing for Drugs Inhibiting the Formation of Gastric Ulcers", <i>Journal of Pharmacological Methods</i> , 8, 33-37, (1982)
	C557	Wickremesinha, E.R., et al., "Taxus Callus Cultures: Initiation, Growth, Optimization, Characterization and Taxol Production", <i>Plant Cell, Tissue and Organ Culture</i> , 35, 181-193, (1993)
	C558	Wickremesinha, E.R., et al., "Taxus Cell Suspension Cultures: Optimizing Growth and Production of Taxol", <i>J. Plant Physiol.</i> , 144, 183-188, (1994)
	C559	Wilensky, et al., "Regional and Arterial Localization of Radioactive Microparticles after Local Delivery by Unsupported Porous Balloon Catheters", <i>American Heart Journal</i> , 129, 852-859 (May 1995)
	C560	Wilensky, R.L., et al., "A Prospective, Randomized, Double-Blind, Dose-Escalation Study Evaluating the Safety and Tolerability of Cytochalasin B to Reduce Vascular Remodeling Following Percutaneous Transluminal Coronary Angioplasty", Abstract, 46 th Annual Scientific Session of the American College of Cardiology, 1 p., (1997)
	C561	Williams, J.K., et al., "The Estrogen Receptor Agonist/Antagonist Tamoxifen Inhibits Progression of Coronary Artery Atherosclerosis in Monkeys", <i>Circulation</i> , 92, November 1995 AHA Meeting, (October 15, 1995)
	C562	Willson, T.M., et al., "Dissection of the Molecular Mechanism of Action of GW5638, a Novel Estrogen Receptor Ligand, Provides Insights into the Role of Estrogen Receptor in Bone", <i>Endocrinology</i> , 138(9), (September 1997)
	C563	Winokur et al., "Expression of transforming growth factors β 1, 2, and 3 following vascular injury," <i>J. Cell Biochem., Suppl.</i> 15C:G414 (Abstr.) (1991)
	C564	Winslow, R., "Going for the Flow", <i>The Wall Street Journal</i> , (Oct. 23, 1995)
	C565	Winternitz, C.I. et al., "Development of a Polymetric Surgical Paste Formulation for Taxol", <i>Pharmaceutical Research</i> , 13 368-375 (1996)
	C566	Wiseman, H., "Tamoxifen as an Antioxidant and Cardioprotectant", <i>Biochem. Soc. Symp.</i> , 61, 209-219, (1995)
	C567	Wiseman, L.R., et al., "Toremifene -- A Review of its Pharmacological Properties and Clinical Efficacy in the Management of Advanced Breast Cancer", <i>Drugs</i> , 54, 141-160, (July 1997)
	C568	Witherup, K.M., et al., "Taxus Spp. Needles Contain Amounts of Taxol Comparable to the Bark of <i>Taxus brevifolia</i> : Analysis and Isolation", <i>Journal of Natural Products</i> , 53, 1249-1255, (Sep./Oct., 1990)
	C569	Wolf, Y.G., et al., "Antibodies Against Transforming Growth Factor Betal Suppress Intimal Hyperplasia in a Rat Model", <i>J. Clin. Invest.</i> , 93, 1172-1178, (Mar. 1994)
	C570	Wrana, et al., "Mechanism of Activation of the TGF-B Receptor", <i>Nature</i> , 370 341-347, (August 4, 1994)
	C571	Wright et al., "Cytoctasin Inhibition of Slow Tension Increase in Rat Aortic Rings", <i>Am. J. Physion.</i> , 267 H1437-H1446 (1994)
	C572	Wright et al., "Percutaneous Endovascular Stents: An Experimental Study," <i>Radiology</i> 1984 Nov;153(P):206 Abs 593.
	C573	Wright et al., "Percutaneous Endovascular Stents: An Experimental Evaluation," <i>Radiology</i> 1985;1:69-72.
	C574	Wu et al., "Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation," <i>Transplant. Porc.</i> , 23:238-240 (1991)
	C575	Wu et al., "The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscel cell proliferation: an in vitro and in vivo study," <i>J. Pharmacol. Sci.</i> 94:252-60 (2004)

	C576	Wu, <i>et al.</i> , "Silicone-covered Seft-expanding Metallic Stents for the Palliation of Malignant Esophageal Obstruction and Esophagorespiratory Fistulas: Experience in 32 Patients and a Review of the Literature," <i>Gastrointest. Endosc.</i> 1994; 40:22-33
	C577	Yamamoto et al., "Ribozyme oligonucleotides against transforming growth facotr-beta inhibited neointimal formation after vascular injury in rat model: potential application of ribozyme strategy to treat cardiovascular disease," <i>Circulation</i> , 102(11):1308-14 (2000)
	C578	Yang, N., et al., "Developing Particle-mediated Gene-transfer Technology for Research Into Gene Therapy of Cancer", <i>Molecular Medicine Today</i> , 476-481, (1996)
	C579	Yang, N.N., et al., "Estrogen Receptor: One Transcription Factor, Two Genomic Pathways", <i>Calcified Tissue Intl.</i> , 54, 342, (1994)
	C580	Yang, N.N., et al., "Identification of an Estrogen Response Element Activated by Metabolites of 17Beta-Estradiol and Raloxifene", <i>Science</i> , 273, 1222-1225, (Oct. 30, 1996)
	C581	Young H., et al., "Pharmacokinetics and Biodistribution of Radiolabelled Idoxifene: Prospects for the Use of PET in the Evaluation of a Novel Antioestrogen for Cancer Therapy", <i>Nucl. Med. Biol.</i> , 22, 405-411, (May 1995)
	C582	Zhang, L. et al., "MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized and tamoxifen-treated nude mice", <i>Oncogen</i> , 15, 2093-2108, (1997)
	C583	Ziegler, J. "Raloxifene, Retinoids, and Lavender: AMe Too@ Tamoxifen Alternatives Under Study", <i>Journal of the National Cancer Institute</i> , 88, 1100-1102, (1996)
	C584	Zohlhofer et al., "Rapamycin effects transcriptional programs in smooth muscle cells controlling proliferative and inflammatory properties," <i>Mol. Pharmacol.</i> 65:880-889 (2004)
	C585	Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Civil Action No. 03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
	C586	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Volume 1, Civil Action No.03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
	C587	Appendix To Answering Memorandum In Opposition To Plaintiffs' Motion For A Preliminary Injunction, Volume 2, Civil Action No.03-283 Dated 4/3/03, U.S. District Court for the District of Delaware
	C588	BSC's Answering Brief in Opposition to Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the '536 Patent
	C589	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are Not Anticipated by the Asserted Prior Art
	C590	BSC's Reply Brief in Further Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536
	C591	Complaint , Civil Action No. 03-283, Filed 3/13/03, U.S. District Court for the District of Delaware
	C592	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that Claims 6 and 8 of the Ding '536 Patent are Not Anticipated by the Asserted Prior Art
	C593	Cordis' Answering Brief in Opposition to BSC's Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536
	C594	Cordis' Answering <i>Markman</i> Brief on the Construction of Terms in the Ding '536 Patent
	C595	Declaration Of Brian G. Firth, Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C596	Declaration Of Dr. Jeffrey W. Moses, M.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C597	Declaration Of Dr. Martin B. Leon, M.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C598	Declaration Of Dr. Paul S. Teirstein, M.D., F.A.C.C., Civil Action No. 03-283 SLR, Dated 3/28/03, U.S. District Court for the District of Delaware
	C599	Declaration Of Dr. Peter Fitzgerald, M.D., Ph.D., Civil Action No. 03-283 SLR, Dated 3/31/03, U.S. District Court for the District of Delaware
	C600	Declaration Of Dr. Richard E. Kuntz, M.D. M.Sc., Civil Action No. 03-283 SLR, Dated 3/21/03, U.S. District Court for the District of Delaware
	C601	Declaration Of Eric Simso, Civil Action No. 03-283, Dated 3/20/03, U.S. District Court for the District of Delaware
	C602	Declaration Of Jermone Segal, M.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of Delaware
	C603	Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 Dated 3/20/03, U.S. District Court for the District of Delaware
	C604	Defendants' Answer, Counterclaim And Demand For Jury Trial, Civil Action No. 03-283, Filed 4/7/03, U.S.

		District Court for the District of Delaware
	C605	Opening Expert Report Of Robson F. Storey, Ph.D., Civil Action No. 03-283 SLR, Dated 5/23/03, U.S. District Court for the District of Delaware
	C606	Opening Expert Report Of Stephen R. Hanson, Ph.D., Civil Action No. 03-283 SLR, Dated 5/23/03, U.S. District Court for the District of Delaware
	C607	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Opening Claim Construction Brief
	C608	Plaintiffs Boston Scientific Scimed, Inc. and Boston Scientific Corporation's Rebuttal Claim Construction Brief
	C609	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that Claims 6 and 8 of the '536 Patent are Not Anticipated by the Asserted Prior Art
	C610	Plaintiffs BSC's Memorandum in Support of its Motion for Summary Judgment that the Cypher Stent Infringes Claims 6 and 8 of U.S. Patent No. 6,120,536 Patent
	C611	Plaintiffs' Opening Brief In Support Of Their Motion For Preliminary Injunction, Civil Action No. 03-283 Filed 3/20/03, U.S. District Court for the District of Delaware
	C612	Plaintiffs' Reply Brief In Support Of their Motion For Preliminary Injunction, Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
	C613	Plaintiffs' Reply To Defendant's Counterclaim, Civil Action No. 03-283 Filed 4/21/03, U.S. District Court for the District of Delaware
	C614	Preliminary Injunction Hearing Transcript, Volume A, Civil Action No. 03-27 (SLR), Dated 7/21/03, U.S. District Court for the District of Delaware
	C615	Preliminary Injunction Hearing Transcript, Volume B, Civil Action No. 03-27 (SLR), Dated 7/22/03, U.S. District Court for the District of Delaware
	C616	Preliminary Injunction Hearing Transcript, Volume C, Civil Action No. 03-27 (SLR), Dated 7/23/03, U.S. District Court for the District of Delaware
	C617	Rebuttal Expert Report Of Kiman Park. Ph.D., Civil Action No.03-283 SLR, Dated 6/2/03, U.S. District Court for the District of Delaware
	C618	Redacted Public Version: Cordis' Opening <i>Markman</i> Brief on the Construction of Terms in the Ding '536 Patent
	C619	Redacted Public Version: Opening Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent
	C620	Reply Brief in Support of Cordis' Motion for Summary Judgment Barring BSC from Asserting Equivalents for Certain Limitations of the Ding Patent
	C621	Second Declaration Of Jerome Segal, M.D., Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
	C622	Second Declaration Of Kinam Park, Ph.D., Civil Action No. 03-283 SLR, Dated 4/10/03, U.S. District Court for the District of Delaware
	C623	Goodnight, S.H., "The Effects of n-3 Fatty Acids on Atherosclerosis and the Vascular Response to Injury", Arch. Pathol. Lab. Med., 117, 102-106, (January, 1993)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.